WO2002088356A1 - Proteine de recepteur couple par proteine g et adn comportant cette proteine - Google Patents

Proteine de recepteur couple par proteine g et adn comportant cette proteine Download PDF

Info

Publication number
WO2002088356A1
WO2002088356A1 PCT/JP2002/004200 JP0204200W WO02088356A1 WO 2002088356 A1 WO2002088356 A1 WO 2002088356A1 JP 0204200 W JP0204200 W JP 0204200W WO 02088356 A1 WO02088356 A1 WO 02088356A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
salt
coupled receptor
receptor protein
compound
Prior art date
Application number
PCT/JP2002/004200
Other languages
English (en)
Japanese (ja)
Inventor
Takeo Moriya
Takashi Ito
Yasushi Shintani
Nobuyuki Miyajima
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of WO2002088356A1 publication Critical patent/WO2002088356A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel G protein-coupled receptor protein derived from human testis, a salt thereof, and a DNA encoding the same.
  • G protein-coupled receptor Yuichi protein or 7-transmembrane receptor Yuichi protein (7TMR).
  • G protein-coupled receptor protein is present on the surface of each functional cell in living cells and organs, and is a target for molecules that regulate the function of those cells and organs, such as hormones, neurotransmitters, and biologically active substances. Plays a physiologically important role.
  • the receptor transmits a signal into the cell through binding to a physiologically active substance, and this signal causes various reactions such as suppression of activation and activation of the cell.
  • G protein-coupled receptor protein Elucidating the relationship between substances that regulate complex functions in cells and organs of various organisms and their specific receptor proteins, especially G protein-coupled receptor protein, is important for various organisms. It will elucidate the functions of cells and organs and provide a very important means for drug development closely related to those functions.
  • physiological functions are regulated under the control of many hormones, hormone-like substances, neurotransmitters or bioactive substances.
  • bioactive substances exist in various parts of the body, It regulates its physiological functions through Recept Yuichi protein.
  • Recept Yuichi protein There are many unknown hormones, neurotransmitters, and other physiologically active substances in the living body, and the structure of their receptor proteins has not yet been reported. In addition, it is often unknown whether subtypes exist in known receptor overnight proteins.
  • the G protein-coupled receptor is useful for searching for a new physiologically active substance (that is, a ligand) using its signaling effect as an index, and for searching for an agonist or antagonist for the receptor.
  • a physiologically active substance that is, a ligand
  • an agonist or an anthony gonist against the receptor is prepared by analyzing the physiological action of the receptor from an inactivation experiment (knockout animal) of the receptor. It is also possible.
  • These ligands, agonists or antagonists to the receptor can be expected to be used as preventive and / or therapeutic or diagnostic agents for diseases associated with dysfunction of G protein-coupled receptors.
  • the decrease or enhancement of the function of the receptor in the living body based on the gene mutation of the G protein-coupled receptor often causes some disease.
  • not only administration of an antagonist or agonist to the receptor but also introduction of the receptor gene into a living body (or a specific organ) or introduction of an antisense nucleic acid to the receptor gene.
  • introduction of the receptor gene into a living body (or a specific organ) or introduction of an antisense nucleic acid to the receptor gene can also be applied to gene therapy.
  • the nucleotide sequence of the receptor is essential information for examining the presence or absence of a deletion or mutation in the gene, and the gene of the receptor is responsible for the disease involved in the dysfunction of the receptor. It can also be applied to prophylactic and / or therapeutic and diagnostic agents.
  • the present invention provides a novel G protein-coupled receptor protein useful as described above. That is, a novel G protein-coupled receptor protein or its partial peptide or a salt thereof, and a polynucleotide (DNA, RNA and a derivative thereof) encoding the G protein-coupled receptor protein or its partial peptide are prepared. Containing polynucleotide (DNA, RNA and derivatives thereof), a recombinant vector containing the polynucleotide, a transformant carrying the recombinant vector, the G protein-coupled receptor protein or a salt thereof.
  • a production method, an antibody against the G protein-coupled receptor protein or a partial peptide or a salt thereof, a compound that changes the expression level of the G protein-coupled receptor protein, and a G protein-coupled receptor protein Method for determining ligands for G protein, coupling of ligand to the G protein Type Recept with Yuichi Protein Screening method for compounds that change binding properties (angiagonists, agonists) or salts thereof, screening kits, ligands obtainable by using the screening methods or screening kits, and the G protein-coupled receptor Yuichi protein (Antagonist, agonist) or a salt thereof, and a compound that alters the binding between a ligand and the G protein-coupled receptor protein (antagonist, agonist) or the G protein It is intended to provide a drug or the like containing a compound that changes the expression level of a conjugated receptor protein or a salt thereof. Disclosure of the invention
  • the present inventors have conducted extensive research and have succeeded in isolating cDNA encoding a novel G protein-combined receptor Yuichi protein derived from human testis and analyzing its entire nucleotide sequence. . Then, when this base sequence was translated into an amino acid sequence, the first to seventh transmembrane regions were confirmed on the hydrophobicity plot, and the protein encoded by these cDNAs was conjugated to a seven-transmembrane G protein. Type receptor protein. The present inventors have further studied based on these findings, and as a result, have completed the present invention. That is, the present invention
  • G protein-coupled receptor protein or a salt thereof which comprises the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or 5;
  • G protein-conjugated receptor which comprises the amino acid sequence represented by SEQ ID NO: 1 or 5, or a salt thereof;
  • polynucleotide according to (4) which is DNA
  • polynucleotide according to (5) having the nucleotide sequence of SEQ ID NO: 2 or 6;
  • the antibody according to (12) which is a neutralizing antibody that inactivates signal transmission of the G protein-coupled receptor protein according to (1);
  • the G protein-coupled receptor according to (1) which can be obtained by using the G protein-coupled receptor according to (1) or the partial peptide according to (3) or a salt thereof.
  • a ligand comprising the G protein-coupled receptor protein according to (1) or the partial peptide according to (3) or a salt thereof.
  • a medicament comprising a compound or a salt thereof, which alters the expression level of the G protein-coupled receptor Yuichi protein according to (1), which can be obtained by using the screening method according to (27).
  • a pharmaceutical comprising the compound or a salt thereof, which alters the amount of the G protein-coupled receptor protein according to (1) in the cell membrane obtainable by using the screening method according to (28).
  • a compound that activates the G protein-coupled receptor protein described in (1) or a salt thereof is contacted with a cell containing the G protein-coupled receptor protein described in (1).
  • a compound that activates the G protein-coupled receptor protein or its salt described in (1) above and a test compound, which contains the G protein-coupled receptor protein described in (1) above A ligand characterized by measuring and comparing cell stimulating activity mediated by a G protein-coupled receptor protein when contacted with a cell and a G protein-coupled receptor protein described in (1) above. Or a method of screening for a compound or a salt thereof that changes the binding property to a salt thereof,
  • the compound that activates the G protein-coupled receptor protein described in (1) above is angiotensin, bombesin, cannabinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, Purin, vasopleucine, oxytocin, PACAP (e.g., PACAP27, PAC ⁇ 38), secretin, glucagon, calcitonin, adrenomedullin, somatos, GHRH, CRF, ACTH, GRP, PTH, VIP (Vasoactive Intesty) Nal polypeptide), somatostin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene-related peptide), leukotriene, pancreatastatin, prostaglandin, thromboxane, adenosine, adrenaline, chemokine insulin Family (eg, CXC chem
  • the ligand which can be obtained by using the screening kit according to any one of the above (44) to (46), and the G protein-coupled receptor Yuichi protein or a salt thereof according to the above (1) A compound that changes the binding property or a salt thereof,
  • Binding between the ligand and the G protein-coupled receptor protein or the salt thereof according to (1) which can be obtained by using the screening kit according to any one of (44) to (46).
  • a medicament comprising a compound or a salt thereof, (49)
  • the above-mentioned agent which is a prophylactic and / or therapeutic agent for central disease, endocrine disease, metabolic disease, cancer, inflammatory disease, cardiovascular disease, respiratory disease, digestive system disease, immune system disease or infectious disease. 21) The pharmaceutical according to (31) or (32),
  • FIG. 1 is a hydrophobicity plot of TGR 20-1.
  • FIG. 2 is a hydrophobicity plot of TGR20-2.
  • FIG. 3 is a diagram showing the amino acid sequence of TGR20-11 in one-letter code.
  • FIG. 4 is a diagram showing the amino acid sequence of TGR20-12 in one-letter code.
  • FIG. 5 is a diagram showing the distribution of TGR20 expression tissues. BEST MODE FOR CARRYING OUT THE INVENTION
  • the G protein-coupled receptor protein of the present invention may be the same as or similar to the amino acid sequence represented by SEQ ID NO: 1 or 5 (FIGS. 2 and 4). It is a receptor protein containing a substantially identical amino acid sequence.
  • the receptor protein of the present invention can be used, for example, in any cells (eg, spleen cells, nerves, etc.) of mammals (eg, humans, guinea pigs, rats, mice, rabbits, bushes, sheep, horses, monkeys, etc.).
  • mammals eg, humans, guinea pigs, rats, mice, rabbits, bushes, sheep, horses, monkeys, etc.
  • Cells glial cells, knee / 3 cells, bone marrow cells, mesangial cells, Langerhans cells, epidermal cells, epithelial cells, endothelial cells, fibroblasts, fiber cells, muscle cells, fat cells, immune cells (eg, macrophages , T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells, osteoblasts, osteoclasts , Mammary cells, hepatocytes or stromal cells, or their precursors, stem cells or cancer cells, etc.) or cells of the blood system (eg, leukocytes, erythrocytes), or those cells Any tissue present, for example, the brain, various parts of the brain (eg, olfactory bulb, nucleus pulposus, basal sphere, hippocampus, thalamus, hypothalamus, hypothalamus,
  • the amino acid sequence substantially the same as the amino acid sequence represented by SEQ ID NO: 1 or 5 includes, for example, about 50% of the amino acid sequence represented by SEQ ID NO: 1 or 5 Or more, preferably about 60% or more, more preferably about 70% or more, further preferably about 80% or more, particularly preferably about 90% or more, and most preferably about 95% or more. And the like.
  • Examples of the protein having an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 1 of the present invention include, for example, a protein having an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 1 Proteins having substantially the same activity as the amino acid sequence represented by SEQ ID NO: 1 are preferred.
  • Examples of the protein having an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 5 of the present invention include, for example, a protein having an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 5
  • a protein having substantially the same activity as the amino acid sequence represented by SEQ ID NO: 5 is preferred.
  • substantially the same activity examples include a ligand binding activity and a signal transduction activity. Substantially the same means that their activities are the same in nature. Therefore, the activities such as ligand binding activity and signal transduction activity are equivalent (eg, about 0.01 to 100 times, preferably about 0.5 to 20 times, more preferably about 0.5 to 20 times). However, the quantitative factors such as the degree of activity and the molecular weight of the protein may be different.
  • the measurement of the activity such as the ligand binding activity and the signal information transmission activity can be performed according to a known method.
  • the activity can be measured according to a ligand determination method described later, ie, a screening method.
  • the receptor protein of the present invention includes: 1) one or more or more amino acids in the amino acid sequence represented by SEQ ID NO: 1 or 5 (preferably, about 1 to 30, more preferably 1 to 1); An amino acid sequence in which about 0, more preferably several (1 to 5) amino acids have been deleted, (2) 1 or 2 or more (preferably 1 to 3) in the amino acid sequence represented by SEQ ID NO: 1 or 5 About 0 amino acids, more preferably about 1 to 10 amino acids, still more preferably several (1 to 5) amino acids; 3 an amino acid sequence represented by SEQ ID NO: 1 or 5 Or an amino acid sequence in which two or more (preferably about 1 to 30, more preferably about 1 to 10, and more preferably several (1 to 5)) amino acids have been substituted with other amino acids , Or ⁇ ⁇ ⁇ ⁇ ⁇ Proteins containing an amino acid sequence obtained by combining them are also used.
  • the receptor protein has the N-terminus (amino terminus) at the left end and the C-terminus (carboxyl terminus) at the right end according to the convention of peptide labeling.
  • the receptor protein of the present invention including the receptor protein containing the amino acid sequence represented by SEQ ID NO: 1 or 5, has a carboxyl group (1-COOH), a carboxylate (- COO—), amide (—CONH 2 ) or ester (one COOR).
  • R in the ester e.g., methyl, Echiru, n- propyl, alkyl groups such as isopropyl or n _ butyl, for example, 3 cyclopentyl Le, cyclohexane, etc.
  • cyclohexyl - 8 cycloalkyl group for example, phenyl, alpha - C 6 _ 12 Ariru groups such as naphthyl, for example, benzyl, phenylene Lou C Bok 2 alkyl groups Moshikuwahi such phenethyl - C 7 _ 14 Ararukiru groups such as ⁇ - Nafuchiru C Bok 2 alkyl group such as naphthylmethyl In addition, a bivaloyloxymethyl group commonly used as an oral ester is used.
  • the receptor protein of the present invention has a carboxyl group (or carboxylate) at a position other than the C-terminal
  • a protein in which the carboxyl group is amidated or esterified is also included in the receptor protein of the present invention.
  • the ester in this case, for example, the above-mentioned C-terminal ester and the like are used.
  • the receptor protein of the present invention include, for example, a human testis-derived receptor protein TGR20 containing the amino acid sequence represented by SEQ ID NO: 1. 1, a human testis-derived receptor protein having an amino acid sequence represented by SEQ ID NO: 5, such as TGR20_2, is used.
  • the partial peptide of the receptor protein of the present invention may be any partial peptide of the receptor protein of the present invention described above.
  • the receptor protein molecules of the present invention those which are exposed outside the cell membrane and have receptor binding activity may be used.
  • a partial peptide of the receptor Yuichi protein having the amino acid sequence represented by SEQ ID NO: 1 or 5 it is considered that it is an extracellular region (hydrophilic (Hydrophi 1ic) site) in the hydrophobicity plot analysis.
  • the peptide containing the analyzed part Further, a peptide partially containing a hydrophobic (Hydrophobic) site can also be used.
  • a peptide containing individual domains may be used, but a peptide containing a plurality of domains at the same time may be used.
  • the number of amino acids of the partial peptide of the present invention is at least 20 or more, preferably 50 or more, more preferably 100 or more of the amino acid sequences constituting the receptor protein of the present invention.
  • Peptides having an amino acid sequence are preferred.
  • a substantially identical amino acid sequence refers to an amino acid sequence of about 50% or more, preferably about 60% or more, more preferably about 70% or more, further preferably about 80% or more, and particularly preferably Represents an amino acid sequence having about 90% or more, most preferably about 95% or more homology.
  • the partial peptide of the present invention has one or more (preferably about 1 to 10, more preferably several (1 to 5)) amino acids in the above amino acid sequence deleted. Or 1 or 2 or more (preferably, about 1 to 20; more preferably, about 1 to 10; more preferably, several (1 to 5)) amino acids are added to the amino acid sequence. Or 1 or 2 or more (preferably about 1 to 10, more preferably several, more preferably about 1 to 5) amino acids in the amino acid sequence are replaced with other amino acids. It may be.
  • the C-terminal of the partial peptide of the present invention may be any of a carboxyl group (one COOH), a carboxylate (—COO—), an amide (one C ⁇ NH 2 ) and an ester (one C ⁇ OR). .
  • the partial peptide of the present invention has an N-terminal methionine residue in which the amino group of the methionine residue is protected by a protecting group, and is formed by cleavage of the N-terminal side in vivo.
  • a protecting group examples include those in which Gin is pyroglutamine-oxidized, those in which the substituent on the side chain of the amino acid in the molecule is protected with an appropriate protecting group, and those in which a sugar chain is bonded, such as a so-called glycopeptide.
  • the C-terminal of the partial peptide of the present invention may be a carboxyl group (one COOH carboxylate (—C ⁇ 0-), an amide (one CO NH 2 ), or an ester (—COOR).
  • Examples of the salt of the receptor protein or its partial peptide of the present invention include a physiologically acceptable salt with an acid or a base, and particularly preferably a physiologically acceptable acid addition salt.
  • Such salts include, for example, salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) or organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid) , Succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) and the like.
  • inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
  • organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid
  • Succinic acid tartaric acid, citric acid, malic acid, oxa
  • the receptor protein of the present invention or a salt thereof can be produced from the above-mentioned mammalian cell or tissue by a known method for purifying the receptor protein, or encodes the receptor protein of the present invention described later. It can also be produced by culturing a transformant containing the DNA of interest. Also, the protein can be produced by the protein synthesis method described later or according to the method.
  • a commercially available resin for protein synthesis can be used.
  • resins include, for example, chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamine resin, PAM Resin, 4-hydroxymethylmethylphenylacetamidomethyl resin, polyacrylamide resin, 4- (2 ', 4'-dimethoxyphenyl-hydroxymethyl) phenoxy resin, 4- (2', 4'-dimethoxyphenyl Two-way Fmoc aminoethyl) phenoxy resin.
  • an amino acid having an ⁇ -amino group and a side chain functional group appropriately protected is condensed on the resin in accordance with the sequence of the target protein according to various known condensation methods.
  • the protein is cleaved from the resin, and at the same time, various protecting groups are removed.
  • an intramolecular disulfide bond formation reaction is carried out in a highly diluted solution to obtain the target protein or its amide.
  • the protected amino acid may be added directly to the resin with a racemization inhibitor additive (eg, HOBt, HOOBt) or pre-protected as a symmetric anhydride or HOBt ester or HOOBt ester.
  • the amino acid can be added to the resin after activation.
  • the solvent used for activating the protected amino acid or condensing with the resin can be appropriately selected from solvents known to be usable for the protein condensation reaction.
  • acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methylvinylidone, halogenated hydrocarbons such as methylene chloride and chloroform, alcohols such as trifluoroethanol , Sulfoxides such as dimethyl sulfoxide, ethers such as pyridine, dioxane, and tetrahydrofuran; nitriles such as acetate nitrile and propionitrile; esters such as methyl acetate and ethyl acetate; or an appropriate mixture thereof.
  • acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methylvinylidone
  • halogenated hydrocarbons such as methylene chloride and chloroform
  • alcohols such as trifluoroethanol
  • the reaction temperature is appropriately selected from the range known to be usable for the protein bond formation reaction, and is usually selected from the range of about 12 O: to 50.
  • Activated key The amino acid derivative is usually used in a 1.5 to 4-fold excess.
  • Examples of the protecting group for the amino group of the starting material include Z, Boc, tertiary pentyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarponyl, C-Z, Br-Z, a Damantyloxycarponyl, trifluoroacetyl, phthaloyl, formyl, 2-ditrophenylsulfenyl, diphenylphosphinothioyl, Fmoc and the like are used.
  • the lipoxyl group may be, for example, alkyl esterified (for example, methyl, ethyl, propyl, butyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-adamantyl, etc.).
  • alkyl esterified for example, methyl, ethyl, propyl, butyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-adamantyl, etc.
  • aralkyl esterification for example, benzyl ester, 4-nitrobenzyl ester, 4-methoxybenzyl ester, 4-methyl benzyl ester, benzhydryl esterification
  • phenacyl esterification It can be protected by benzyloxycarbonyl hydrazide, tert-butoxycarbonyl hydrazide, trityl hydrazide and the like.
  • the hydroxyl group of serine can be protected, for example, by esterification or etherification.
  • a group suitable for the esterification for example, a lower alkanol group such as an acetyl group, an aroyl group such as a benzoyl group, a group derived from carbonic acid such as a benzyloxycarbonyl group and an ethoxycarbonyl group, and the like are used.
  • groups suitable for etherification include a benzyl group, a tetrahydrovinyl group, a t-butyl group, and the like.
  • the protecting group of the phenolic hydroxyl group of tyrosine for example, B zl, C l 2 - B zl, 2- two Torobenjiru, B r- Z, such as tertiary butyl is used.
  • activated carboxyl groups of the raw materials include, for example, corresponding acid anhydrides, azides, active esters [alcohols (eg, pentachlorophenol, 2,4,5-trichloromouth phenol, 2,4- Dinitrophenol, cyanomethyl alcohol, paranitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimide, and ester with H ⁇ Bt).
  • active esters eg, pentachlorophenol, 2,4,5-trichloromouth phenol, 2,4- Dinitrophenol, cyanomethyl alcohol, paranitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimide, and ester with H ⁇ Bt.
  • activated amifu group of the raw material for example, a corresponding phosphoric amide is used.
  • Methods for removing (eliminating) the protecting group include, for example, catalytic reduction in a hydrogen stream in the presence of a catalyst such as Pd-black or Pd-carbon, or hydrogen fluoride anhydride, methanesulfonic acid, or the like.
  • a catalyst such as Pd-black or Pd-carbon, or hydrogen fluoride anhydride, methanesulfonic acid, or the like.
  • Acid treatment with trifluoromethanesulfonic acid, trifluoroacetic acid or a mixture thereof, base treatment with diisopropylethylamine, triethylamine, piperidine, piperazine, etc., and reduction with sodium in liquid ammonia are also used.
  • the elimination reaction by the above-mentioned acid treatment is generally carried out at a temperature of about 120 to about 40.
  • the protection of the functional group which should not be involved in the reaction of the raw materials, the protecting group, the elimination of the protective group, the activation of the functional group involved in the reaction, and the like can be appropriately selected from known groups or known means.
  • a peptide (protein) chain is added to the amino group side to a desired chain length.
  • the protein except for the ⁇ -amino group protecting group at the N-terminus of the peptide chain and the protecting group at the C-terminal carbonyl group is produced, and both proteins are condensed in a mixed solvent as described above. Details of the condensation reaction are the same as described above.
  • all the protecting groups are removed by the above-mentioned method to obtain a desired crude protein.
  • the crude protein is purified by using various known purification means, and the main fraction is freeze-dried to obtain an amide of the desired protein.
  • ester of a protein for example, after condensing the ⁇ _ carboxyl group of the carboxy terminal amino acid with a desired alcohol to form an amino acid ester, the ester of the desired protein can be obtained in the same manner as the protein amide. Can be obtained.
  • the partial peptide of the protein of the present invention or a salt thereof can be produced according to a known peptide synthesis method or by cleaving the protein of the present invention with an appropriate peptidase.
  • a method for synthesizing a peptide for example, any of a solid phase synthesis method and a liquid phase synthesis method may be used. That is, the target peptide can be produced by condensing a partial peptide or amino acid capable of constituting the protein of the present invention with the remaining portion, and if the product has a protecting group, removing the protecting group. .
  • Known methods for condensation and elimination of protecting groups include, for example, the methods described in the following 1 to 5.
  • the partial peptide of the present invention can be purified and isolated by a combination of ordinary purification methods, for example, solvent extraction, distillation, column chromatography, liquid chromatography, and recrystallization.
  • the partial peptide obtained by the above method is a free form In some cases, it can be converted to an appropriate salt by a known method. Conversely, when it is obtained as a salt, it can be converted to a free form by a known method.
  • the polynucleotide encoding the receptor protein of the present invention may be any polynucleotide as long as it contains the above-described nucleotide sequence (DNA or RNA, preferably DNA) encoding the receptor protein of the present invention. Is also good.
  • the polynucleotide is a DNA encoding the receptor protein of the present invention, RNA such as mRNA, and may be double-stranded or single-stranded. In the case of double-stranded, it may be double-stranded DNA, double-stranded RNA or DNA: RNA hybrid. If single stranded, it may be the sense strand (ie, the coding strand) or the antisense strand (ie, the non-coding strand).
  • the polynucleotide encoding the receptor protein of the present invention for example, a method described in the known experimental medicine special edition "New PCR and its application” 15 (7), 1997 or a method analogous thereto
  • the mRNA of the receptor protein of the present invention can be quantified.
  • the DNA encoding the receptor protein of the present invention may be any of genomic DNA, a genomic DNA library, the above-described cDNA derived from cells and tissues, the above-described cDNA library derived from cells and tissues, and synthetic DNA.
  • the vector used for the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like. Alternatively, it can be directly amplified by reverse transcriptase polymerase chain reaction (hereinafter abbreviated as RT-PCR method) using a total RNA or mRNA fraction prepared from the cells and tissues described above.
  • the DNA encoding the receptor protein of the present invention is, for example, a DNA containing the base sequence represented by SEQ ID NO: 2 or 6, or the base represented by SEQ ID NO: 2 or 6. It has DNA that hybridizes under high stringent conditions to DNA having a sequence, and has substantially the same activity (eg, ligand binding activity, signal transduction activity, etc.) as the receptor protein of the present invention. Any DNA may be used as long as it encodes a receptor protein having the DNA. It is highly stringent with DNA having the nucleotide sequence represented by SEQ ID NO: 2.
  • the DNA that hybridizes under the conditions is, for example, about 70% or more, preferably about 80% or more, more preferably about 90% or more, and most preferably about 95% or more with the base sequence represented by SEQ ID NO: 2.
  • Examples of the DNA that hybridizes with the DNA having the nucleotide sequence of SEQ ID NO: 6 under high stringent conditions include, for example, about 70% or more, preferably about 70% or more of the nucleotide sequence of SEQ ID NO: 6
  • a DNA containing a nucleotide sequence having a homology of 80% or more, more preferably about 90% or more, and most preferably about 95% or more is used.
  • Hybridization is performed according to a known method or a method analogous thereto, for example, the method described in Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). Can be done. When a commercially available library is used, it can be performed according to the method described in the attached instruction manual. More preferably, it can be performed according to high stringent conditions.
  • the high stringent conditions include, for example, a sodium concentration of about 19 to 40 mM, preferably about 19 to 2 OmM, and a temperature of about 50 to 70, preferably about 60 to 65 :.
  • a sodium concentration of about 19 to 40 mM, preferably about 19 to 2 OmM
  • a temperature of about 50 to 70, preferably about 60 to 65 :.
  • the case where the sodium concentration is about 19 mM and the temperature is about 65 is most preferable.
  • DNA encoding the receptor protein TGR 20-1 containing the amino acid sequence represented by SEQ ID NO: 1 a DNA containing the base sequence represented by SEQ ID NO: 2
  • DNA encoding the receptor protein TGR 201-11 having the amino acid sequence represented by SEQ ID NO: 5 a DNA having the base sequence represented by SEQ ID NO: 6 and the like are used.
  • a part of the nucleotide sequence of the DNA encoding the receptor protein of the present invention, or a polynucleotide containing a part of the nucleotide sequence complementary to the DNA, is a polynucleotide encoding the following partial peptide of the present invention. Not only does it encompass DNA, but also RNA.
  • a polynucleotide (nucleic acid) can hybridize to RNA of a G protein-coupled receptor protein gene and can inhibit the synthesis or function of the RNA, or can inhibit the synthesis or function of G protein-coupled receptor protein.
  • G protein-coupled receptor protein gene expression can be regulated and controlled through interaction with quality-related RNA.
  • Polynucleotides that are complementary to a selected sequence of G protein-coupled receptor protein-related RNA and that can specifically hybridize with G protein-coupled receptor protein-associated RNA are It is useful for regulating and controlling the expression of G protein-coupled receptor protein gene in vitro and in vitro, and is also useful for treating or diagnosing diseases and the like.
  • the term "corresponding" means having homology or being complementary to a particular sequence of nucleotides, base sequences or nucleic acids, including genes. “Corresponding” between a nucleotide, base sequence or nucleic acid and a peptide (protein) usually refers to the amino acid of the peptide (protein) in the instructions derived from the nucleotide (nucleic acid) sequence or its complement.
  • 5'-end hairpin loop, 5'-end 6 base-ba-repeat, 5'-end untranslated region, 5'-end untranslated region, polypeptide translation initiation codon, protein coding region, ORF translation termination Codons, 3 'untranslated region, 3' palindrome region, and 3 'hairpin loop may be selected as preferred regions of interest, but any region within the G protein coupled conjugate receptor protein Can be selected as
  • Antisense polynucleotides include polynucleotides containing 2-dexoxy-D-ribose, polynucleotides containing D-ribose, and other types of polynucleotides that are N-glycosides of purine or pyrimidine bases.
  • Nucleotide or non-nucleotide backbone Other polymers that have a specific bond (eg, commercially available protein nucleic acids and synthetic sequence-specific nucleic acid polymers) or other polymers that contain special bonds (provided that the polymer is a base polymer such as that found in DNA or RNA). Pairing (contains a nucleotide having a configuration permitting attachment of a base)). They can be double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, and even DNA: RNA hybrids, and can further comprise unmodified polynucleotides (or unmodified oligonucleotides).
  • Nucleotides as well as those with known modifications, eg, labeled, capped, methylated, or one or more natural nucleotides replaced with analogs, as known in the art , Modified with an intramolecular nucleotide, such as those having an uncharged bond (eg, methylphosphonate, phosphotriester, phosphoramidate, olebamate, etc.), a charged bond or a sulfur-containing bond (eg, phosphorothioate) , Such as proteins (nucleases, nucleases, inhibitors, etc.) Has side-chain groups such as syn, antibody, signal peptide, poly-L-lysine, etc.
  • an intramolecular nucleotide such as those having an uncharged bond (eg, methylphosphonate, phosphotriester, phosphoramidate, olebamate, etc.), a charged bond or a sulfur-containing bond (eg, phosphorothioate) ,
  • nucleic acid may include not only those containing purine and pyrimidine bases but also those having other modified heterocyclic bases. Such modifications may include methylated purines and pyrimidines, acylated purines and pyrimidines, or other heterocycles.
  • Modified nucleotides and modified nucleotides may also be modified at the sugar moiety, e.g., where one or more hydroxyl groups have been replaced with halogens, aliphatic groups, etc., or functionalities such as ethers, amines, etc. It may be converted to a group.
  • the antisense polynucleotide (nucleic acid) of the present invention is an RNA, a DNA, or a modified nucleic acid (RNA, DNA).
  • modified nucleic acids include sulfur derivatives of nucleic acids, thiophosphate derivatives, and polynucleoside amides. And those that are resistant to degradation of oligonucleoside amides, but are not limited thereto.
  • the antisense nucleic acid of the present invention can be preferably designed according to the following policy. That is, to make the antisense nucleic acid more stable in the cell, to increase the cell permeability of the antisense nucleic acid, to have a greater affinity for the target sense strand, and to be more toxic if it is toxic. Make sense nucleic acid less toxic.
  • the antisense nucleic acids of the present invention may contain altered or modified sugars, bases, or bonds, may be provided in special forms such as ribosomes or microspheres, may be applied by gene therapy, It could be given in additional form.
  • additional forms include polycations, such as polylysine, which act to neutralize the charge on the phosphate backbone, and lipids, which enhance interaction with cell membranes or increase nucleic acid uptake.
  • polycations such as polylysine, which act to neutralize the charge on the phosphate backbone
  • lipids which enhance interaction with cell membranes or increase nucleic acid uptake.
  • hydrophobic substances such as phospholipid and cholesterol
  • Preferred lipids for addition include cholesterol and its derivatives (eg, cholesteryl chromate formate, cholic acid, etc.).
  • Such a substance can be attached to the 3 'end or 5' end of a nucleic acid, and can be attached via a base, a sugar, or an intramolecular nucleoside bond.
  • Other groups include cap groups specifically arranged at the 3 'end or the 5' end of nucleic acids, which prevent degradation by nucleases such as exonuclease and RNAse.
  • capping groups include, but are not limited to, hydroxyl-protecting groups known in the art, including glycols such as polyethylene glycol and tetraethylene dalicol.
  • the antisense nucleic acid inhibitory activity is examined using the transformant of the present invention, the in vivo or in vitro gene expression system of the present invention, or the in vivo or in vitro translation system of the G protein-coupled receptor protein. be able to.
  • the cells may be prepared by various methods known in the art. Applicable to
  • the DNA encoding the partial peptide of the present invention may be any DNA containing the above-described nucleotide sequence encoding the partial peptide of the present invention.
  • genomic DNA genomic DNA Any of a library, a cDNA derived from the above-described cells and tissues, a cDNA library derived from the above-described cells and tissues, and a synthetic DNA may be used.
  • the vector used for the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like. Alternatively, it can be directly amplified by Reverse Transcriptase Polymerase Chain Reaction (hereinafter abbreviated as RT-PCR method) using an mRNA fraction prepared from the cells and tissues described above.
  • RT-PCR method Reverse Transcriptase Polymerase Chain Reaction
  • the DNA encoding the partial peptide of the present invention includes, for example, (1) DNA having a partial base sequence of DNA having the base sequence represented by SEQ ID NO: 2 or 6, or (2) sequence It has a DNA that hybridizes under high stringent conditions with DNA having the nucleotide sequence represented by No. 2 or 6, and has substantially the same activity as the receptor protein of the present invention (eg, ligand binding activity,
  • DNA having a partial base sequence of DNA encoding a receptor protein having a signal transduction effect having a signal signaling function is used.
  • Examples of the DNA that hybridizes with the DNA having the nucleotide sequence represented by SEQ ID NO: 2 under high stringent conditions include, for example, about 70% or more, preferably about 80% of the nucleotide sequence represented by SEQ ID NO: 2.
  • DNA containing a nucleotide sequence having a homology of at least about 90% or more, most preferably at least about 95% or more is used.
  • Examples of the DNA that hybridizes with the DNA having the nucleotide sequence represented by SEQ ID NO: 6 under high stringent conditions include, for example, about 70% or more, preferably about 80% or more of the nucleotide sequence represented by SEQ ID NO: 6 DNA having a nucleotide sequence having homology of about 90% or more, most preferably about 95% or more is used.
  • Cloning of the DNA completely encoding the receptor protein of the present invention or a partial peptide thereof includes the receptor protein of the present invention.
  • Selection can be performed by hybridization with a DNA fragment to be coded or labeled with a synthetic DNA. Hybridization can be performed, for example, according to the method described in Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). When a commercially available library is used, the procedure can be performed according to the method described in the attached instruction manual.
  • the DNA base sequence can be converted using PCR or a known kit such as Mutan TM -super Express Km (Takara Shuzo Co., Ltd.) or Mutan TM -K (Takara Shuzo Co., Ltd.) using the ODA-LAPCR method or the Gapped method. It can be carried out according to a known method such as the duplex method or the Kunkel method or a method analogous thereto.
  • the DNA encoding the cloned receptor protein can be used as it is depending on the purpose, or can be used by digesting with a restriction enzyme or adding a linker if desired.
  • the DNA may have ATG as a translation initiation codon at its 5 'end, and TAA, at the end of translation, or at its 3' end at the 3 'end. These translation initiation codon and translation termination codon can also be added using a suitable synthetic DNA adapter.
  • the expression vector of the receptor protein of the present invention may be prepared, for example, by (a) cutting out a DNA fragment of interest from DNA encoding the receptor protein of the present invention, and (mouth) converting the DNA fragment into an appropriate expression vector. It can be produced by ligating downstream of the promoter.
  • E. coli-derived plasmids eg, pCR4, pCR2.1, pBR322, pBR325, pUC12, pUC13
  • Bacillus subtilis-derived plasmids eg, pUB110, pTP5, pC194.
  • Yeast-derived plasmids eg, pSH19, pSH15
  • bacteriophage such as ⁇ phage
  • animal viruses such as retrovirus, vaccinia virus, baculovirus, etc., as well as ⁇ Alll, pXTl, pRc / CMV, pRc / RSV, pc DNA I / Neo, etc. are used.
  • the promoter used in the present invention may be any promoter as long as it is appropriate for the host used for gene expression.
  • SRa Promoter when animal cells are used as host, SRa Promoter, SV40 promoter, LTR motor, CMV Promoter, HSV-TK promoter and the like can be mentioned. Of these, it is preferable to use the CMV promoter, the SR ⁇ promoter, and the like.
  • the host is Eshierihia genus bacterium, trp promoter one, lac flop port motor, re cA promoter evening one, AP L promoter and foremost, etc.
  • l pp promoter Isseki one is, when the host is Bacillus, When the host is yeast, such as SP ⁇ 1 promoter, SP ⁇ 2 promoter, pen P promoter, etc., PH05 promoter, PGK promoter, GAP promoter, ADH promoter and the like are preferable. When the host is an insect cell, a polyhedrin promoter, a P10 promoter and the like are preferable.
  • an expression vector containing, if desired, an enhancer, a splicing signal, a polyA addition signal, a selection marker, and an SV40 replication origin (hereinafter sometimes abbreviated as SV40 ori) may be used.
  • selectable markers include a dihydrofolate reductase (hereinafter sometimes abbreviated as dh fr) gene [methotrexate (MTX) resistance], an ampicillin resistance gene (hereinafter sometimes abbreviated as Amp), Neomycin resistance gene (hereinafter sometimes abbreviated as Neo, G418 resistance), etc.
  • dh fr gene is used as a selection marker using CHO (dh fr ") cells
  • the target gene Can also be selected with a thymidine-free medium.
  • a signal sequence suitable for the host is added to the N-terminal side of the receptor protein of the present invention.
  • the host is a genus Escherichia
  • the PhoA-signal sequence, a 0-A signal sequence, etc. when the host is a Bacillus genus, an ⁇ -amylase signal sequence, a subtilisin, a signal sequence, etc.
  • the host is an animal cell, such as MF, signal sequence, SUC2, signal sequence, etc. Etc. can be used respectively.
  • a transformant can be produced using a vector containing
  • Escherichia bacteria for example, Escherichia bacteria, Bacillus bacteria, yeast, insect cells, insects, animal cells, and the like are used.
  • Escherichia examples include Escherichia coli K12, DH1 [Processing's of the 'National Academy of Sciences of the United States (Proc. Natl. Acad. Sci. USA), Vol. 60, 160 (1968)], JM103 [Nucleic Acids Research, (Nucleic Acids Research), Vol. 9, 309 (198 1)], J J221 [Journalo Journal of Molecular Biology], 120, 517 (1978)], HB 101 [Journal of Molecular Biology, 41, 459 (1969)], C 600 [ Genetics
  • Bacillus bacteria examples include, for example, Bacillus subtilis MI 114 [Gene, 24, 255 (1983)], 207-21 [Journal of Biochemistry, 95 Vol. 87 (1 984)].
  • yeast examples include, for example, Saccharomyces cerevisiae AH22, AH22R-, NA87-11A, DKD-5D, 20B-12, Schizosaccharomyces pombe NCYC 1913, NCYC2036 , Pichia pastoris, etc. are used.
  • insect cells for example, when the virus is AcNPV, a cell line derived from a larva of Spodoptera (Spodoptera frugiperda cell; Sf cell), MG1 cell derived from the midgut of Trichoplusia ni, High Five TM derived from egg of Trichoplusia ni Cells, cells derived from Mamestra brassicae or cells derived from Estigmena acrea are used. Wooly When the virus is BmNP V, a cell line derived from silkworm (Bombyxmori N; BmN cell) or the like is used. Examples of the Sf cell include Sf9 cell (ATCC CRL1711) and Sf21 cell (Vaughn, Jugh et al., In Vivo, 13, 213-217, (1977)) Are used.
  • insects for example, silkworm larvae and the like are used [Maeda et al., Nature, 315, 592 (1985)].
  • animal cells examples include monkey cell COS-7, Vero, Chinese Hams Yuichi cell CHO (hereinafter abbreviated as CHO cell), dh fr gene-deficient Chinese hamster cell CHO (hereinafter abbreviated as CHO (dh fr—) cell). ), Mouse L cells, mouse AtT-20, mouse myeloma cells, rat GH3, and human FL cells.
  • Transformation of Bacillus spp. Can be performed, for example, according to the method described in Molecular & General Genetics, Vol. 168, 11 (1799).
  • Insect cells or insects can be transformed, for example, by the method described in Bio / Technology, 6, 47-55 (1988).
  • a transformant transformed with the expression vector containing A is obtained.
  • a liquid medium is suitable as a medium to be used for culturing, and a carbon source necessary for the growth of the transformant is contained therein.
  • Nitrogen sources inorganic substances and the like.
  • carbon sources include glucose, dextrin, soluble starch, and sucrose.
  • nitrogen sources include ammonium salts, nitrates, corn chip liquor, peptone, potato zein, meat extract, soybean meal, and potato extract.
  • the inorganic or organic substance and the inorganic substance include calcium chloride, sodium dihydrogen phosphate, magnesium chloride and the like.
  • yeast extract, vitamins, growth promoting factors and the like may be added.
  • the pH of the medium is preferably about 5-8.
  • Examples of a medium for culturing the genus Escherichia include, for example, an M9 medium containing glucose and casamino acids (Miller, Journal of Experiments, Molecular Genetics, Journal of Experiments in Molecular Genetics). ), 431-433, Cold Spring Harbor Laboratory, New York 19
  • a drug such as 3 / 3-indolyl acrylic acid can be added to make the promotion work efficiently.
  • cultivation is usually performed at about 15 to 43 for about 3 to 24 hours, and if necessary, aeration and stirring can be applied.
  • the cultivation is usually carried out at about 30 to 40 for about 6 to 24 hours. If necessary, aeration and stirring can be applied.
  • the medium used is 10% serum immobilized in Grace's Insect Medium (Grace, TCC, Nature, 195, 788 (1962)). And the like to which additives such as the above are appropriately added are used.
  • the ⁇ of the culture medium is adjusted to about 6.2 to 6.4. Culture is usually performed at about 27 for about 3 to 5 days, and aeration and agitation are added as necessary.
  • the medium When culturing a transformant in which the host is an animal cell, the medium may be, for example, a MEM medium containing about 5 to 20% fetal bovine serum (Science, 122, 501 (1952)), DMEM medium [Virology, 8, 396 (1959)], RPMI 1640 medium [Journal of the American Medical Association (1992), 519 (1 967)] and 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)] Used.
  • the pH is about 6-8. Culture is usually performed at about 30t: ⁇ 40 for about 15-60 hours, and aeration and agitation are added as necessary.
  • the G protein-coupled receptor overnight protein of the present invention can be produced in the cells, in the cell membrane, or outside the cells of the transformant.
  • the receptor protein of the present invention can be separated and purified from the culture by, for example, the following method.
  • the cells or cells are collected by a known method after culturing, suspended in an appropriate buffer, and subjected to ultrasound, lysozyme and / or After the cells or cells are destroyed by freeze-thawing or the like, a method of obtaining a crude extract of the receptor protein by centrifugation or filtration is used as appropriate.
  • the buffer may contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 TM. If the receptor protein is secreted into the culture solution, after the culture is completed, the supernatant is separated from the cells or cells by a known method, and the supernatant is collected.
  • Receptor contained in the culture supernatant or extract obtained in this way The protein can be purified by appropriately combining known separation and purification methods.
  • These known separation and purification methods mainly include methods using solubility such as salting out and solvent precipitation, dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis, and the like.
  • Methods that use differences in charge methods that use charge differences such as ion-exchange chromatography, methods that use specific novelty such as affinity chromatography, and methods that use reverse-phase high-performance liquid chromatography.
  • Methods using the difference in hydrophobicity, methods using the difference in isoelectric point such as isoelectric focusing, and the like are used.
  • the receptor protein thus obtained when it is obtained in a free form, it can be converted to a salt by a known method or a method analogous thereto, and conversely, when it is obtained in a salt, a known method Alternatively, it can be converted into a free form or another salt by a method analogous thereto.
  • Receptor protein produced by the recombinant can be optionally modified or partially removed by treating it with an appropriate protein modifying enzyme before or after purification.
  • an appropriate protein modifying enzyme for example, trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase and the like are used.
  • the activity of the receptor protein of the present invention or a salt thereof thus produced can be measured by a binding experiment with a labeled ligand, an enzyme immunoassay using a specific antibody, or the like.
  • An antibody against the receptor protein of the present invention or its partial peptide or a salt thereof may be a polyclonal antibody as long as it can recognize the receptor protein of the present invention or its partial peptide or a salt thereof. Any of an antibody and a monoclonal antibody may be used.
  • An antibody against the receptor protein of the present invention, its partial peptide, or a salt thereof may be prepared by using the receptor protein of the present invention as an antigen, It can be produced according to a method for producing an antibody or antiserum.
  • the receptor protein or the like of the present invention is administered to a mammal at a site capable of producing an antibody by administration, itself or together with a carrier or a diluent.
  • a mammal at a site capable of producing an antibody by administration, itself or together with a carrier or a diluent.
  • Complete Freund's adjuvant / Incomplete Freund's adjuvant may be administered to enhance antibody production ability.
  • the administration is usually performed once every 2 to 6 weeks, for a total of 2 to 10 times. Examples of mammals to be used include monkeys, rabbits, dogs, guinea pigs, mice, rats, sheep, goats, and mice and rats are preferably used.
  • monoclonal antibody-producing cells When producing monoclonal antibody-producing cells, select a warm-blooded animal immunized with an antigen, for example, an individual with an antibody titer from a mouse, and collect the spleen or lymph node 2 to 5 days after the final immunization By fusing antibody-producing cells contained therein with myeloma cells, monoclonal antibody-producing hybridomas can be prepared.
  • the antibody titer in the antiserum can be measured, for example, by reacting the antiserum with a labeled receptor protein or the like described later, and then measuring the activity of a labeling agent bound to the antibody.
  • the fusion operation can be carried out according to a known method, for example, the method of Koehler and Mills [Nature, 256, 495 (1975)].
  • the fusion promoter include polyethylene glycol (PEG) and Sendai virus, but PEG is preferably used.
  • myeloma cells examples include NS-1, P3U1, SP2Z0, and the like, with P3U1 being preferred.
  • the preferred ratio between the number of antibody-producing cells (spleen cells) and the number of myeloma cells used is about 1: 1 to 20: 1, and the PEG (preferably, PEG1000 to PEG6000) power is about 10 to 80%.
  • Cell fusion can be carried out efficiently by incubating at about 20 to 40, preferably about 30 to 37 for about 1 to 10 minutes.
  • the hybridomas may be attached to a solid phase (eg, a microplate) on which an antigen such as receptor protein is adsorbed directly or together with a carrier.
  • a solid phase eg, a microplate
  • the culture supernatant is added, and then an anti-immunoglobulin antibody (labeled for cell fusion) If the cells to be treated are mice, an anti-mouse immunoglobulin antibody is used.)
  • a method for detecting the monoclonal antibody bound to the solid phase by adding tin A A method of adding a hybridoma culture supernatant, adding a receptor protein or the like labeled with a radioactive substance, an enzyme, or the like, and detecting a monoclonal antibody bound to a solid phase can be used.
  • the selection of the monoclonal antibody can be carried out according to a known method or a method analogous thereto. Usually, it can be carried out in a medium for animal cells to which HAT (hypoxanthine, aminopterin, thymidine) is added.
  • HAT hyperxanthine, aminopterin, thymidine
  • any medium can be used as long as it can grow a hybridoma.
  • RPMI 1640 medium containing 1 to 20%, preferably 10 to 20% fetal bovine serum, GIT medium containing 1 to 10% fetal bovine serum (Wako Pure Chemical Industries, Ltd.)
  • a serum-free medium for hybridoma culture SFM-101, Nissui Pharmaceutical Co., Ltd.
  • the cultivation temperature is usually from 20 to 40, preferably about 37.
  • the culture time is generally 5 days to 3 weeks, preferably 1 week to 2 weeks.
  • the culture can be usually performed under 5% carbon dioxide.
  • the antibody titer of the culture supernatant of the eight hybridomas can be measured in the same manner as the measurement of the antibody titer in the antiserum described above.
  • Monoclonal antibodies can be separated and purified in the same manner as normal polyclonal antibodies. [Examples: salting out, alcohol precipitation, isoelectric focusing, electrophoresis, ion exchangers (ex. , DEAE), ultracentrifugation, gel filtration, antigen-binding solid phase or specific antibody obtained by collecting only the antibody with an active adsorbent such as protein A or protein G, and dissociating the bond to obtain the antibody. Purification method].
  • the polyclonal antibody of the present invention can be produced according to a known method or a method analogous thereto. For example, a complex of an immunizing antigen (an antigen such as the receptor protein of the present invention) and a carrier protein is formed, and a mammal is immunized in the same manner as in the method for producing a monoclonal antibody described above. Recept Yuichi By collecting antibody-containing substances against proteins, etc., and separating and purifying the antibodies. Can be manufactured.
  • the type of carrier-1 protein and the mixing ratio between carrier and hapten depend on the efficiency of antibody against hapten immunized by cross-linking with carrier. If possible, any material may be cross-linked at any ratio.For example, serum serum albumin, thyroglobulin, keyhole limpet, hemocyanin, etc. may be used in a weight ratio of hapten. On the other hand, a method of coupling at a rate of about 0.1 to 20, preferably about 1 to 5 is used.
  • various condensing agents can be used for force coupling between the hapten and the carrier.
  • an active ester reagent containing a daltaraldehyde, a carbodiimide, a maleimide active ester, a thiol group or a dithioviridyl group is used.
  • the condensation product is administered to a warm-blooded animal itself or together with a carrier or diluent at a site where antibody production is possible.
  • Complete Freund's adjuvant / incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration.
  • the administration can usually be performed once every about 2 to 6 weeks, for a total of about 3 to 10 times.
  • the polyclonal antibody can be collected from blood, ascites, etc., preferably from blood, of the mammal immunized by the above method.
  • the measurement of the polyclonal antibody titer in the antiserum can be performed in the same manner as the measurement of the antibody titer in the serum described above. Separation and purification of the polyclonal antibody can be performed according to the same immunoglobulin separation and purification method as the above-described separation and purification of the monoclonal antibody.
  • the receptor protein of the present invention or its salt, its partial peptide or its salt, and the DNA encoding the receptor protein or its partial peptide are: (1) a ligand (agonist) for the G protein-coupled receptor protein of the present invention; (2) a prophylactic and / or therapeutic agent for a disease associated with dysfunction of the G protein-coupled receptor protein of the present invention, (3) a gene diagnostic agent, (4) a receptor protein of the present invention or A method for screening a compound that changes the expression level of the partial peptide, (5) prevention of various diseases containing a compound that changes the expression level of the receptor protein of the present invention or the partial peptide thereof, and prevention of Z or Is a therapeutic agent; (6) a method for quantifying a ligand for the G protein-coupled receptor protein of the present invention; and (7) a compound that changes the binding property of the ligand to the G protein-coupled receptor protein of the present invention.
  • Compounds that alter the binding between the G protein-coupled receptor Yuichi protein and the ligand of the present invention A prophylactic and / or therapeutic agent for various diseases comprising: (9) quantification of the receptor protein of the present invention or a partial peptide thereof or a salt thereof; (10) a receptor protein of the present invention in a cell membrane or a portion thereof A method for screening a compound that changes the amount of a peptide, (11) a receptor protein of the present invention or a partial peptide thereof in a cell membrane.
  • a prophylactic and / or therapeutic agent for various diseases containing a compound that alters the amount of (12) neutralization by an antibody against the receptor protein of the present invention or its partial peptide or a salt thereof, (13) the present invention Can be used to create a non-human animal having a DNA encoding the G protein-coupled receptor protein.
  • the receptor-binding Atsei system using the recombinant G protein-coupled receptor protein expression system of the present invention, the ligand binding property to a mammal-specific G protein-coupled receptor is changed.
  • Compounds eg, agonist, angelic gonist, etc.
  • the agonist or angelic gonist can be used as an agent for preventing and / or treating various diseases.
  • a receptor protein or a partial peptide of the present invention or a salt thereof hereinafter sometimes abbreviated as a receptor protein of the present invention, etc.
  • a DNA encoding a receptor protein of the present invention or a partial peptide thereof hereinafter, referred to as a peptide.
  • the use of an antibody against the receptor protein of the present invention or the like hereinafter sometimes abbreviated as the antibody of the present invention is specifically described below. .
  • the receptor protein of the present invention overnight or its salt or the partial peptide of the present invention
  • the salt thereof is useful as a reagent for searching for or determining a ligand (agonist) for the receptor protein of the present invention or a salt thereof.
  • the present invention provides a method for determining a ligand for the receptor protein of the present invention, which comprises contacting the receptor protein of the present invention or a salt thereof or the partial peptide of the present invention or a salt thereof with a test compound. Provide a way.
  • Test compounds include known ligands (for example, angiotensin, bombesin, canapinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, purine, vasoprescin, oxotocin, ⁇ ACAP (eg, PACAP 2 7, PACAP 3 8), secretin, glucagon, calcitonin, adrenomedullin, somatos, GHRH, CRF, ACTH, GRP, PTH, VIP (Vasoactive Intestinal and Rerated Polypeptide), somatos Tin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene-related peptide), leukotriene, pancreatastatin, prostaglandin, tropoxane, adenosine, adrenaline, chemokine superfamily ⁇ (eg, IL-8, GROa, GR ⁇ /
  • lysophosphatidic acid LPA
  • sphingosine monomonophosphate etc.
  • mammalian Organization Distillate such as cell culture supernatant is used.
  • tissue extract, the cell culture supernatant, etc. are added to the receptor protein of the present invention, and the cell stimulating activity and the like are measured. Fractionation, and finally a single ligand can be obtained.
  • the ligand determination method of the present invention uses the receptor protein of the present invention or a partial peptide thereof or a salt thereof, or constructs an expression system for a recombinant receptor protein, and By using the receptor binding system using the receptor system, it is possible to bind to the receptor protein of the present invention and to stimulate cell stimulation (for example, release of arachidonic acid, release of acetylcholine, release of intracellular Ca 2+, release of intracellular c AMP generation, intracellular c GMP generation, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, c-fos activation, activity to promote or suppress pH reduction, etc.)
  • This is a method for determining a compound (eg, peptide, protein, non-peptide compound, synthetic compound, fermentation product, etc.) or a salt thereof.
  • the amount of the test compound bound to the receptor protein or the partial peptide is characterized by measuring cell stimulating activity and the like.
  • the present invention provides
  • the labeled test compound When the labeled test compound is brought into contact with the receptor protein expressed on the cell membrane by culturing a transformant containing the DNA encoding the receptor protein of the present invention, the labeled test compound The receptor according to the present invention, wherein the amount of binding to the receptor protein or a salt thereof is measured. Yuichiichi Method for determining ligand for protein,
  • ⁇ Cell stimulating activity via receptor protein (eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+) when a test compound is brought into contact with cells containing the receptor protein of the present invention.
  • Activity or suppression that promotes release, intracellular CAMP generation, intracellular cGMP generation, inositol phosphate production, fluctuations in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, decrease in pH, etc.
  • the receptor protein is Cell stimulating activity (e.g., arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular CAMP generation, intracellular cGMP generation, inositol phosphate production, cell membrane potential fluctuation, intracellular protein Phosphorylation, activation of c-fos, activity of suppressing or reducing pH, etc.), and determination of ligands for the receptor protein or its salt according to the present invention.
  • Cell stimulating activity e.g., arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular CAMP generation, intracellular cGMP generation, inositol phosphate production, cell membrane potential fluctuation, intracellular protein Phosphorylation, activation of c-fos, activity of suppressing or reducing pH, etc.
  • the receptor protein used in the ligand determination method may be any protein as long as it contains the above-described receptor protein of the present invention or the partial peptide of the present invention. A protein expressed in a large amount at night is suitable.
  • the above-described expression method is used. It is preferable that the DNA encoding the receptor protein is expressed in mammalian cells or insect cells. Complementary DNA is usually used as the DNA fragment encoding the protein portion of interest, but is not necessarily limited to this. For example, a gene fragment or a synthetic DNA may be used. In order to introduce the DNA fragment encoding the receptor protein of the present invention into host animal cells and to express them efficiently, the DNA fragment must be introduced into an insect host and used as a baculovirus.
  • Polyhedros is virus (NPV) polyhedrin promoter, SV40-derived promoter, retroviral promoter — Yuichi, meta-mouth thionein promoter, human heat shock It is preferable to incorporate the gene into the downstream of a promoter, cytomegalovirus promoter, SR ⁇ promoter and the like. Examination of the amount and quality of the expressed receptor can be performed by a known method. For example, the method is performed according to the method described in the literature [Nambi, P. et al., The Journal of Biological 'Chemistry (J. Biol. Chem.), 267, 19555-19559, 1992]. Can be.
  • the receptor protein of the present invention or a partial peptide thereof or a salt thereof includes a receptor protein or a partial peptide thereof or a salt thereof purified according to a known method.
  • a cell containing the receptor protein or a cell membrane fraction thereof may be used.
  • the cells When cells containing the receptor protein of the present invention are used in the method for determining a ligand of the present invention, the cells may be immobilized with daltaraldehyde, formalin, or the like.
  • the immobilization method can be performed according to a known method.
  • the cells containing the receptor protein of the present invention include host cells expressing the receptor protein of the present invention.
  • the host cells include Escherichia coli, Bacillus subtilis, yeast, insect cells, animal cells and the like. Is used.
  • the cell membrane fraction refers to a cell membrane-rich fraction obtained by disrupting cells and then obtained by a known method.
  • Cell crushing methods include a method of crushing cells with a Potter-Elvehj em-type homogenizer, Warinda Blender ⁇ Polytron.
  • centrifugal fractionation methods such as differential centrifugation and density gradient centrifugation are mainly used.
  • the cell lysate is centrifuged at a low speed (500 rpm to 300 rpm) for a short time (usually about 1 to 10 minutes), and the supernatant is further spun at a higher speed (150 rpm to 300 rpm).
  • the mixture is centrifuged at 0,000 rpm for 30 minutes to 2 hours, and the resulting precipitate is used as the membrane fraction.
  • the expressed receptor protein and cell-derived proteins were included. It is rich in membrane components such as phospholipids and membrane proteins.
  • the amount of receptor protein in the cells containing the receptor protein and the membrane fraction thereof is preferably 10 3 to 10 8 molecules per cell, more preferably 10 5 to 10 7 molecules per cell. Is preferred.
  • receptor protein fraction a natural receptor protein fraction or a recombinant receptor fraction having an activity equivalent thereto is desirable.
  • equivalent activity refers to equivalent ligand binding activity, signal transduction activity and the like.
  • Labeled test compounds include angiotensin, bombesin, canapinoid, cholecystokinin, dalyumin, serotonin, melatonin, labeled with [], [ 125 I], ["c", [S], etc.
  • Neuropeptide Y opioids, purines, vasopressin, oxatocin, PACAP (e.g., PACAP 27, PACAP 38), secretin, glucagon, calcitonin, adrenomedullin, somato sutin, GHRH, CRF, ACTH, GRP, PTH, VIP ( Basoactive Intestinal and Retained Polypeptide), Somatos Retin, Dopamine, Motilin, Amylin, Bradykinin, CGRP (Calcitonin Gene Reited Peptide), Leukotriene, Pancreastatin, Prostaglandin, Thromboxan, Adenosine, Adrenaline , Chemokines family (eg, IL-8, GROa, GRO / 3, GROr, NAP-2, ENA-78, GCP-2, PF4, IP_10, Mig, PBSF / SDF-1 etc.
  • PACAP e.g., PACAP 27, PACAP 38
  • CXC chemokine subfamily Of the CXC chemokine subfamily; MCAFZMCP-1, MCP-2, MCP-3, MCP-4, eot ax in, RANTES, MIP-1 and MlP-1 ⁇ , HCC-1 and ⁇ I ⁇ -3 ⁇ / LARC, ⁇ I ⁇ -3 ⁇ / ELC, I-309, TARC, MI PF— 1, MI PF— 2 / eot ax in-2, MDC, CC-chemokine subfamily such as DC-CK 1 / PARC, SLC; C chemokine subfamily such as 1 ym photactin; CX3 C chemokine subfamily such as fracta 1 kine etc.), endothelin, enterogastrin, histamine, neuro Tensin, TRH, pancreatic polypeptide, galanin, lysophosphatidic acid (LPA), and sphingosine 1-phosphate are preferred.
  • a cell containing the receptor protein of the present invention or a membrane fraction of the cell is first suitable for the method for determination.
  • Prepare a standard sample of the receptor by suspending in a buffer.
  • the buffer may be any buffer such as a phosphate buffer of pH 4 to 10 (preferably pH 6 to 8) or a buffer of tris-hydrochloric acid, which does not inhibit the binding between the ligand and the receptor protein.
  • various proteins such as detergents such as CHAP S, Tween-80 TM (Kao Ichi Atlas Co., Ltd.), digitonin and dexcholate, and serum albumin and gelatin are buffered. Can also be added.
  • a protease inhibitor such as PMSF, leptin, E-64 (manufactured by Peptide Research Laboratories), and peptide suptin can be added for the purpose of suppressing the degradation of the receptor and the ligand by the protease. To 0.0 lm.
  • a test compound having a count (B-NSB), which is obtained by subtracting the non-specific binding amount (N SB) from the total binding amount (B), exceeding 0 cpm is used as a receptor according to the present invention.
  • Select as a ligand for one protein or its salt can do.
  • cell stimulating activity via the receptor protein for example, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, cell Or the activity of promoting or inhibiting intracellular C GMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, c-fos activation, pH reduction, etc.
  • cell stimulating activity via the receptor protein for example, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, cell Or the activity of promoting or inhibiting intracellular C GMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, c-fos activation, pH reduction, etc.
  • cell stimulating activity via the receptor protein for example, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, cell Or the activity of promoting or inhibiting intracellular C GMP production, in
  • the kit for determining a ligand binding to the receptor protein of the present invention or a salt thereof contains the receptor protein of the present invention or a salt thereof, the partial peptide or a salt thereof of the present invention, and the receptor protein of the present invention. It contains a cell or a membrane fraction of a cell containing the receptor protein of the present invention.
  • kits for determining a ligand of the present invention include the following.
  • the C HO cells expressing the receptor protein of the present invention 1 2-well plates were passaged with 5 X 1 0 5 cells / well, at 37, 2 days of culture at 5% C_ ⁇ 2, 9 5% air did thing.
  • Test compounds that are poorly soluble in water should be dissolved in dimethylformamide, DMSO, methanol, etc.
  • the same as the labeled compound is prepared at a concentration 100 to 1000 times higher.
  • Examples of the ligand capable of binding to the receptor protein or a salt thereof of the present invention include substances specifically present in organs such as blood, brain, large intestine, spleen, spleen, and ovary, and the like.
  • angiotensin, bombesin cana pinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, purine, vasoprescin, oxaxin, PACAP (e.g., PACAP 27, PACAP 38) , Secretin, glucagon, calcitonin, adrenomedullin, somatos, GHRH, CRF, ACTH, GRP, PTH, VIP (Vasoactive Intestinal and Reputed Polypeptide), somatos, dopamine, motilin, Amylin, Radikinin, CGRP (calcitonin gene relayed peptide), leukotriene, pancreastatin,
  • the receptor protein of the present invention or the DNA encoding the receptor protein can be prepared according to the action of the ligand. It can be used as a medicament such as an agent for preventing and / or treating a disease associated with dysfunction of the receptor protein of the present invention.
  • the DNA encoding the receptor protein of the present invention is useful as an agent for preventing and / or treating a disease associated with dysfunction of the safe and low toxic receptor protein of the present invention.
  • the receptor protein of the present invention has about 39% homology at the amino acid sequence level to KIAA0758 [DNA Res., 5 (5), 277-286 (1998)] which is a G protein-coupled receptor protein. It is a novel seven-transmembrane receptor protein that is recognized.
  • the DNA encoding the receptor protein or the receptor protein of the present invention may be a central disease (eg, Alzheimer's disease, dementia, eating disorder, depression, epilepsy, etc.), an endocrine disease (eg, Addison's disease, Cushing's syndrome, brown cells) Species, primary aldosteronism, menopause, endometriosis, gonadal dysfunction, thyroid dysfunction, pituitary dysfunction, etc., metabolic diseases (eg, diabetes, dyslipidemia, diabetic complications, obesity, gout, Cataract, hyperlipidemia, etc.), cancer (for example, non-small cell lung cancer, ovarian cancer, prostate cancer, stomach cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, etc.), inflammatory disease ( For example, allergies, asthma, rheumatism, arthritis, nephritis, hepatitis, retinopathy, cystitis, pneumonia, etc., cardiovascular diseases (eg, hypertension, cardiac hypertrophy, stenosis) Heart
  • the receptor protein of the present invention When used as the above-mentioned prophylactic and / or therapeutic agent, it can be formulated according to conventional means.
  • the DNA encoding the receptor protein of the present invention (hereinafter sometimes abbreviated as the DNA of the present invention) is used as the above-described prophylactic and / or therapeutic agent
  • the DNA of the present invention may be used alone or as a retrovirus.
  • a suitable vector such as a virus vector
  • the DNA of the present invention can be administered as it is or together with an adjuvant for promoting uptake, using a gene gun or a catheter such as Hyde-mouth gel power catheter.
  • DNA encoding the receptor protein of the present invention or (2) the receptor protein may be, if necessary, orally as tablets, capsules, elixirs, microcapsules, etc., coated with sugar or water or water. It can be used parenterally in the form of an injectable solution such as a sterile solution with a pharmaceutically acceptable liquid or a suspension.
  • the receptor protein of the present invention or (2) DNA encoding the receptor protein is generally used together with known physiologically acceptable carriers, flavors, excipients, vehicles, preservatives, stabilizers, binders, and the like. Recognized formulation It can be manufactured by mixing in the unit dosage form required for practice. The amount of the active ingredient in these preparations is such that a suitable dosage in the specified range can be obtained.
  • Additives that can be incorporated into tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc. Swelling agents such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, and flavoring agents such as peppermint, cocoa oil or cherry.
  • the unit dosage form is a capsule, the above type of material can further contain a liquid carrier such as an oil or fat.
  • Sterile compositions for injection can be formulated according to standard pharmaceutical practice, such as dissolving or suspending the active substance in vehicles such as water for injection, and naturally occurring vegetable oils such as sesame oil and coconut oil. it can.
  • aqueous solution for injection for example, physiological saline, isotonic solution containing glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.) and the like are used.
  • Agents such as alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, polyethylene daricol), non-ionic surfactants (eg, polysorbate 80 TM, HCO-50) .
  • the oily liquid for example, sesame oil, soybean oil, and the like are used. Good.
  • prophylactic and / or therapeutic agent examples include a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride, etc.), a stabilizer (for example, , Human serum albumin, polyethylene glycol, etc.), preservatives (eg, benzyl alcohol, phenol, etc.), antioxidants and the like.
  • a buffer for example, a phosphate buffer, a sodium acetate buffer
  • a soothing agent for example, benzalkonidum chloride, proactive hydrochloride, etc.
  • a stabilizer for example, Human serum albumin, polyethylene glycol, etc.
  • preservatives eg, benzyl alcohol, phenol, etc.
  • antioxidants and the like examples include a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride
  • the preparations obtained in this way are safe and have low toxicity, they can be used, for example, in mammals (eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.). Can be administered.
  • mammals eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.
  • the dose of the receptor protein of the present invention varies depending on the administration subject, target organ, symptoms, administration method, and the like.
  • oral administration in general, for example, in a cancer patient (as 60 kg), It is about 0.1 mg to 100 mg per day, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg per day.
  • parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, etc.
  • it is usually used for cancer patients (as 6 O kg).
  • the amount converted per 60 kg can be administered.
  • the dosage of the DNA of the present invention varies depending on the administration subject, the target organ, the condition, the administration method, and the like.
  • oral administration in general, for example, in a cancer patient (as 6 O kg), one dose is required.
  • parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, etc.
  • it is usually used, for example, for cancer patients (as 6 O kg).
  • the dose can be administered in terms of 60 kg.
  • the DNA of the present invention can be used as a probe to produce the receptor protein of the present invention in mammals (eg, human, rat, mouse, egret, sheep, bush, horse, cat, dog, monkey, etc.). Since abnormalities (DNA abnormalities) in DNA or mRNA encoding the partial peptide can be detected, for example, damage, mutation, or decreased expression of the DNA or mRNA, and increased or excessive expression of the DNA or mRNA, etc. It is useful as a gene diagnostic agent for.
  • the above-described genetic diagnosis using the DNA of the present invention includes, for example, the well-known Northern Hybridization and the PCR-SSCP method (Genomics, Vol. 5, pp. 874-879 (1989), Proc. Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, pp. 2766-2770 (1989)) Can be implemented.
  • the DNA of the present invention when used as a probe, can be used for screening for a compound that changes the expression level of the receptor protein or its partial peptide of the present invention.
  • the present invention relates to, for example, (i) non-human mammals: (1) blood, (2) specific organs, (3) tissues or cells isolated from the organs, or (ii) the receptor of the present invention contained in a transformant or the like.
  • the present invention provides a method for screening a compound that changes the expression level of the receptor protein or its partial peptide of the present invention by measuring the mRNA amount of one protein or its partial peptide.
  • the measurement of the amount of mRNA of the receptor protein of the present invention or its partial peptide is specifically performed as follows.
  • non-human mammals for example, mice, rats, rabbits, higgs, bushus, horses, cats, dogs, monkeys, etc., more specifically, dementia rats, obese mice, arteriosclerosis ⁇ A heron, a tumor-bearing mouse, etc.
  • a drug eg, an anti-dementia drug, a blood pressure lowering drug, an anti-cancer drug, an anti-obesity drug, etc.
  • physical stress eg, After a certain period of time, such as infiltration stress, electric shock, light and dark, low temperature, etc., blood or specific organs (eg, brain, liver, spleen, large intestine, knee, ovary, etc.) or isolated from organs Obtained tissue or cells.
  • the mRNA of the receptor protein of the present invention or its partial peptide contained in the obtained cells can be obtained by, for example, extracting mRNA from cells or the like by an ordinary method, for example, using a technique such as TaQManPCR. And can be analyzed by performing Northern blotting by known means.
  • a transformant expressing the receptor protein of the present invention or its partial peptide is prepared according to the above method, and the mRNA of the receptor protein of the present invention or its partial peptide contained in the transformant is prepared. Can be quantified and analyzed in the same manner.
  • Screening for a compound that changes the expression level of the receptor protein or its partial peptide of the present invention comprises:
  • the test compound When culturing the transformant according to a conventional method, the test compound is mixed in a medium, and after culturing for a certain period of time (1 day to 7 days, preferably 1 day to 3 days, more preferably 2 days to 3 days) (After day), the amount can be determined by quantifying and analyzing the mRNA amount of the receptor protein of the present invention or its partial peptide contained in the transformant.
  • the compound or a salt thereof obtained by using the screening method of the present invention has an action of changing the expression level of the receptor protein of the present invention or a partial peptide thereof.
  • G protein-coupled receptor eg, arachidonic acid Release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular cGMP generation, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of
  • Examples of the compound include a peptide, a protein, a non-peptidic compound, a synthetic compound, a fermentation product, and the like. These compounds may be novel compounds or known compounds.
  • the compound that enhances the cell stimulating activity is useful as a safe and low toxic drug for enhancing the physiological activity of the receptor protein or the like of the present invention.
  • the compound that reduces the cell stimulating activity is useful as a safe and low-toxic drug for reducing the physiological activity of the receptor protein of the present invention or the like.
  • a compound or a salt thereof obtained by using the screening method of the present invention is used as a pharmaceutical composition, it can be carried out according to a conventional method.
  • tablets, capsules, elixirs, microcapsules, sterile solutions, suspensions, and the like can be prepared in the same manner as the above-mentioned drug containing the receptor protein of the present invention.
  • the preparations obtained in this way are safe and have low toxicity, they can be used, for example, in mammals (eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.). Can be administered.
  • mammals eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.
  • the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptoms, administration method, and the like. About 0.1 to 100 mg / day, preferably about 1.0 to 50 mg / day, more preferably about 1.0 to 20 mg / day. In the case of parenteral administration, the single dose varies depending on the administration subject, target organ, symptoms, administration method, etc. Is one It is convenient to administer about 0.01 to 30 mg, preferably about 0.1 to 20 mg, more preferably about 0.1 to 10 mg per day by intravenous injection. In the case of other animals, the dose can be administered in terms of 60 kg.
  • a preventive and / or therapeutic agent for various diseases containing a compound that changes the expression level of the receptor protein or its partial peptide of the present invention
  • the receptor protein of the present invention is considered to play some important role in vivo such as central function. Therefore, the compound that alters the expression level of the receptor protein or its partial peptide of the present invention can be used as an agent for preventing and / or treating a disease associated with dysfunction of the receptor protein of the present invention. .
  • examples of the disease associated with dysfunction of the receptor protein of the present invention include central diseases (eg, Alzheimer's disease, dementia, eating disorders, depression, epilepsy, etc.), endocrine diseases (eg, Addison's disease, Cushing's syndrome, pheochromocytoma, primary aldosteronism, menopause, endometriosis, gonadal dysfunction, thyroid dysfunction, pituitary dysfunction, etc., metabolic disorders (eg, diabetes, dyslipidemia, diabetic complications) , Obesity, gout, cataract, hyperlipidemia, etc.), cancer (for example, non-small cell lung cancer, ovarian cancer, prostate cancer, gastric cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, etc.) , Inflammatory diseases (eg, allergy, asthma, rheumatism, arthritis, nephritis, hepatitis, retinopathy, cystitis, pneumonia, etc.), cardiovascular diseases (eg, hypertension, cardiac hypertrophy) An
  • the compound when used as a prophylactic and / or therapeutic agent for a disease associated with dysfunction of the receptor protein of the present invention, it can be formulated according to a conventional method. it can.
  • the compound can be used as a sugar-coated tablet, capsule, elixir, microcapsule or the like as needed, orally, or aseptic solution with water or another pharmaceutically acceptable liquid. It can be used parenterally or in the form of injections such as suspensions.
  • the compound is mixed with known physiologically acceptable carriers, flavoring agents, excipients, vehicles, preservatives, stabilizers, binders, and the like in a unit dosage form generally required for the practice of pharmaceutical preparations. It can be manufactured by The amount of the active ingredient in these preparations is such that a suitable dosage in the specified range can be obtained.
  • Additives that can be incorporated into tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc. Swelling agents such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, and flavoring agents such as peppermint, cocoa oil or cherry.
  • the unit dosage form is a capsule, the above type of material can further contain a liquid carrier such as an oil or fat.
  • Sterile compositions for injection can be formulated according to standard pharmaceutical practice, such as dissolving or suspending the active substance in vehicles such as water for injection, and naturally occurring vegetable oils such as sesame oil and coconut oil. it can.
  • aqueous liquid for injection include physiological saline, isotonic solution containing glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.) and the like.
  • Agents such as alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, polyethylene daricol), nonionic surfactants (eg, polysorbate 80 TM, HCO-50) .
  • the oily liquid for example, sesame oil, soybean oil and the like are used, and may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol.
  • prophylactic and / or therapeutic agent examples include a buffer (for example, a phosphate buffer and a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride, etc.), a stabilizer (for example, , Human serum albumin, polyethylene glyco And preservatives (eg, benzyl alcohol, phenol, etc.), antioxidants and the like.
  • a buffer for example, a phosphate buffer and a sodium acetate buffer
  • a soothing agent for example, benzalkonidum chloride, proactive hydrochloride, etc.
  • a stabilizer for example, Human serum albumin, polyethylene glyco And preservatives (eg, benzyl alcohol, phenol, etc.), antioxidants and the like.
  • the prepared injection solution is usually filled in a suitable ampoule.
  • the preparations obtained in this way are safe and have low toxicity, they can be used, for example, in mammals (eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.). Can be administered.
  • mammals eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.
  • the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptoms, administration method, and the like. However, in the case of oral administration, for example, in a cancer patient (as 6 O kg), one dose is generally used. About 0.1 to per day: L0 Omg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg.
  • the single dose varies depending on the administration target, target organ, symptoms, administration method, etc., for example, usually in the form of an injection, for example, a cancer patient (as 6 O kg)
  • the amount converted per 60 kg can be administered.
  • the ligand of the present invention for the G protein-coupled receptor protein has a binding property to the ligand. Can be.
  • the quantification method of the present invention can be used, for example, in combination with a competition method. That is, the ligand concentration in the specimen can be measured by bringing the specimen into contact with the receptor protein of the present invention or the like. Specifically, for example, it can be used according to the method described in the following (1) or (2) or a method analogous thereto.
  • the ligand and the receptor of the present invention can be obtained by using the receptor protein of the present invention or by constructing an expression system for a recombinant receptor protein or the like and using a receptor-binding assay system using the expression system.
  • a compound that changes the binding property to a protein or the like eg, a peptide, a protein, a non-peptidic compound, a synthetic compound, a fermentation product, etc.
  • a salt thereof can be efficiently screened.
  • Such compounds include (ii) cell stimulating activity via G protein-coupled receptors (eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular c A compound that has the activity of promoting or inhibiting GMP production, inositol phosphate production, fluctuations in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, reduction of pH, etc.
  • G protein-coupled receptors eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular c
  • G protein-coupled receptors eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular c
  • G protein-coupled receptors eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular
  • Ligand and G protein of the present invention A compound that enhances the binding force to the conjugated receptor protein, or (2) the ligand and the G protein-coupled receptor protein of the present invention. Compound that reduces the binding strength and the like are included (the compound of the above (I) is not preferred to be screened by the ligand determination methods described above).
  • the present invention relates to (i) the case where the receptor protein of the present invention or its partial peptide or a salt thereof is brought into contact with a ligand, and ( ⁇ ) the case where the receptor protein of the present invention or its partial peptide or a salt thereof is present. And a compound or a salt thereof that alters the binding property between the ligand and the receptor protein of the present invention or a partial peptide thereof or a salt thereof, which is compared with a case where the ligand and the test compound are brought into contact with each other. Is provided.
  • the screening method of the present invention is characterized in that, in the cases (i) and (ii), for example, the amount of a ligand bound to the receptor protein and the like, the cell stimulating activity and the like are measured and compared. .
  • the present invention provides
  • a compound that activates the receptor protein or the like of the present invention eg, a ligand for the receptor protein or the like of the present invention
  • a cell containing the receptor protein or the like of the present invention e.g, a cell containing the receptor protein or the like of the present invention
  • Cell stimulating activity via receptor receptor eg, arachidonic acid release
  • a compound activating the receptor protein of the present invention and a test compound are brought into contact with cells containing the receptor protein of the present invention.
  • a compound that activates the receptor protein or the like of the present invention (for example, a ligand for the receptor protein or the like of the present invention) is treated with a trait containing the DNA of the present invention.
  • the transformant is cultured and the receptor is brought into contact with the receptor protein or the like of the present invention expressed on the cell membrane, the compound of the present invention that activates the receptor protein or the like and the test compound are the DNA of the present invention.
  • Cell stimulatory activity through receptor X eg, arachidonic acid release, acetilco Phosphorus release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular cGMP generation, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, pH A compound that changes the binding property between the ligand and the receptor protein of the present invention, etc.
  • Other provides a method of screening a salt thereof.
  • a cell containing the protein-coupled receptor protein such as a rat
  • a candidate compound is obtained using the tissue or its cell membrane fraction (primary screening), and then the candidate compound actually inhibits the binding of human G protein-coupled receptor protein to ligand A test (secondary screening) was needed to confirm whether or not this was the case. If the cell, tissue or cell membrane fraction is used as it is, other receptor proteins will also be present. Therefore, it has been difficult to actually screen for an agonist or an antagonist of the desired receptor protein.
  • the use of the human receptor protein of the present invention eliminates the need for primary screening, and makes it possible to efficiently screen for a compound that inhibits the binding of a ligand to a G protein-coupled receptor protein. it can. Further, it is possible to easily evaluate whether the screened compound is an agonist or an antagonist.
  • any protein may be used as long as it contains the above-described receptor protein of the present invention.
  • Cell membrane fractions of mammalian organs containing the receptor protein and the like of the present invention are suitable.
  • human-derived organs are extremely available Because of its difficulty, it is suitable to use, for example, a human-derived receptor protein expressed in large amounts by using a recombinant, etc. for screening.
  • the above method is used to produce the receptor protein of the present invention, etc., but it is preferable to carry out the expression by expressing the DNA of the present invention in mammalian cells or insect cells.
  • a complementary DNA is used for the encoding DNA fragment, but is not necessarily limited to this.
  • a gene fragment or a synthetic DNA may be used.
  • the DNA fragment should be transferred to a nuclear polyhedrosis belonging to a baculovirus using an insect as a host.
  • Virus nuclear polyhedros is virus; NPV
  • polyhedrin promoter SV40-derived promoter, retroviral promoter, meta-mouth thionine promoter, human heat shock promoter, cytomegalovirus promoter, It is preferably incorporated downstream, such as the SR a promoter.
  • Examination of the amount and quality of the expressed receptor can be performed by a known method. For example, it can be carried out according to the method described in the literature [Nambi, P. et al., The 'Journal of Biological Chemistry (J. Biol. Chem.), 267, 19555-19559, 1992]. it can.
  • the protein containing the receptor protein of the present invention may be a receptor protein purified according to a known method or the like.
  • a cell containing a protein or the like may be used, or a membrane fraction of a cell containing the receptor protein or the like may be used.
  • the cell when a cell containing the receptor protein of the present invention or the like is used, the cell may be immobilized with daltaraldehyde, formalin, or the like.
  • the immobilization method can be performed according to a known method.
  • Cells containing the receptor protein of the present invention and the like refer to host cells expressing the receptor protein and the like.
  • Examples of the host cells include Escherichia coli, Bacillus subtilis, yeast, insect cells, and animals. Cells and the like are preferred.
  • the cell membrane fraction refers to a cell membrane-rich fraction obtained by disrupting cells and then obtained by a known method.
  • Methods for crushing cells include crushing cells with a Potter-Elvehj em-type homogenizer, Waring Blender ⁇ Polytron. (Kinematica), crushing by ultrasonic waves, crushing by ejecting cells from a narrow nozzle while applying pressure with a French press or the like.
  • centrifugal fractionation methods such as differential centrifugation and density gradient centrifugation are mainly used.
  • the cell lysate is centrifuged at low speed (500 rpm to 300 rpm) for a short time (usually about 1 to 10 minutes), and the supernatant is further centrifuged (150 rpm to 1000 rpm). The mixture is centrifuged at 300 rpm for 30 minutes to 2 hours, and the resulting precipitate is used as a membrane fraction.
  • the membrane fraction is rich in the expressed receptor protein and other membrane components such as cell-derived phospholipids and membrane proteins.
  • the receptor protein fraction is preferably a natural receptor protein fraction or a recombinant receptor protein fraction having an activity equivalent to that of the natural receptor protein fraction.
  • equivalent activity refers to equivalent ligand binding activity, signal transduction action, and the like.
  • labeled ligand a labeled ligand, a labeled ligand analog compound and the like are used.
  • ligands labeled with [ 3 H], C 125 1], [ 14 C], [ 35 S] and the like are used.
  • a cell or a membrane fraction of the cell containing the receptor or the like of the present invention is subjected to screening.
  • Prepare the receptor protein preparation by resuspending it in a buffer suitable for screening.
  • the buffer may be a phosphate buffer having a pH of 4 to 10 (preferably pH 6 to 8), or a buffer that does not inhibit the binding of a ligand such as Tris-HCl buffer to the receptor protein. Any may be used.
  • Surfactants such as CHAPS, Tween-80 TM (Kao-Atlas), digitonin, and dexcholate can also be added to the buffer to reduce non-specific binding.
  • protease inhibitors such as PMS F, Leptin, E-64 (manufactured by Peptide Research Laboratories), and Peptidin can be added for the purpose of suppressing receptor and ligand degradation by proteases. . To 0.0 lm.
  • T 4 M ⁇ 1 T ID test compound M Prepare a reaction tube containing a large excess of unlabeled ligand to determine the amount of non-specific binding (NSB)
  • the reaction is about 0 to 50, preferably about 4 to 37, After about 20 minutes to 24 hours, preferably about 30 minutes to 3 hours
  • the reaction solution is filtered through a glass fiber filter paper and washed with an appropriate amount of the same buffer, and the radioactivity remaining on the glass fiber filter paper is measured using a liquid scintillation counter or
  • the specific binding amount (B -NSB) for example, a test compound with 50% or less It can be selected as a candidate substance capable of.
  • a cell stimulating activity mediated by the receptor protein eg, arachidone
  • Acid release acetylcholine release
  • intracellular Ca2 + release intracellular cAMP production
  • intracellular cGMP production inositol phosphate production
  • cell membrane potential fluctuation intracellular protein phosphorylation, activation of c-fos, pH Activity that promotes or suppresses reduction, etc.
  • cells containing the receptor protein of the present invention and the like are cultured on a multi-well plate or the like. Before conducting screening, replace the cells with a fresh medium or an appropriate buffer that is not toxic to cells, add test compounds, etc., incubate for a certain period of time, extract cells or collect the supernatant. The products produced are quantified according to the respective method.
  • the production of substances eg, arachidonic acid
  • the assay may be performed by adding an inhibitor against the degrading enzyme.
  • an activity such as inhibition of cAMP production can be detected as an activity of inhibiting production of cells whose basal production has been increased by forskolin or the like.
  • cells expressing an appropriate receptor protein are required.
  • examples of cells expressing the receptor protein of the present invention include cell lines having the natural receptor protein of the present invention and cell lines expressing the recombinant receptor protein of the present invention. desirable.
  • test compounds for example, peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, etc. are used, and these compounds are novel compounds. Or a known compound.
  • a screening kit for a compound or a salt thereof that alters the binding property of a ligand to the receptor protein or the like of the present invention includes a cell containing the receptor protein of the present invention or the like, the protein of the present invention or the like. Or a cell membrane fraction containing the receptor protein of the present invention.
  • screening kit of the present invention examples include the following. 1. Screening reagent
  • Filtration can be performed by filtration through a 0.45 / zm filter, and stored at 4 or may be prepared at the time of use.
  • the receptions evening CHO cells expressing an protein of the present invention 1 2-well plates and passaged 5 X 1 0 5 or holes, 3 7, 5% C 0 2, and cultured for 2 days in 9 5% air thing.
  • the compound or a salt thereof obtained by using the screening method or the screening kit of the present invention is a compound having an action of changing the binding property between the ligand and the receptor protein of the present invention.
  • Cell stimulating activity via G protein-coupled receptor eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP generation, intracellular cGMP generation, inositol phosphate production, cell membrane potential fluctuation, cell (A so-called agonist for the receptor protein of the present invention) having an activity of promoting or inhibiting the phosphorylation of internal proteins, activation of c-fos, reduction of pH, etc.
  • a compound having no cell-stimulating activity a so-called angonist for the receptor protein of the present invention
  • Examples of the compound include a peptide, a protein, a non-peptidic compound, a synthetic compound, a fermentation product, and the like. These compounds may be novel compounds or known compounds.
  • the agonist against the receptor protein or the like of the present invention has the same activity as the physiological activity of the ligand for the receptor protein or the like of the present invention, it is useful as a safe and low-toxic drug according to the ligand activity. is there.
  • the antagonist of the present invention for the receptor protein or the like can suppress the physiological activity of the ligand for the receptor or the like of the present invention, it is useful as a safe and low-toxic drug for suppressing the ligand activity. is there.
  • a compound that enhances the binding force between the ligand and the G protein-coupled receptor protein of the present invention is a safe and low toxic compound for enhancing the physiological activity of the ligand for the receptor protein of the present invention and the like. It is useful as a novel medicine.
  • the compound that decreases the binding force between the ligand and the G protein-coupled receptor protein of the present invention is useful as a safe and low-toxic drug for reducing the physiological activity of the ligand for the receptor protein or the like of the present invention. is there.
  • the compound or its salt obtained by using the screening method or the screening kit of the present invention is used as the above-mentioned pharmaceutical composition, it can be carried out according to a conventional method.
  • tablets, capsules, elixirs, microcapsules, sterile solutions, suspensions, and the like can be prepared in the same manner as in the above-described medicine containing the receptor protein of the present invention.
  • the preparations obtained in this way are safe and have low toxicity, they can be used, for example, in mammals (eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.). Can be administered.
  • mammals eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.
  • the dose of the compound or its salt depends on the subject of administration, target organ, symptoms, administration method, etc.
  • oral administration in general, for example, in a cancer patient (assuming 60 kg), about 0. 0 to 10 mg / day, preferably about 1.0 to 5 mg / day 0 mg, more preferably about 1.0-20 mg.
  • parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, and the like. In this case, it is convenient to administer about 0.01 to 30 mg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 10 mg per day by intravenous injection. It is. In the case of other animals, the dose can be administered in terms of 60 kg.
  • a prophylactic and / or therapeutic agent for various diseases containing a compound (agonist, angonist) that changes the binding property between the G protein-coupled receptor protein and the ligand of the present invention.
  • the receptor protein of the present invention is considered to play some important role in vivo, such as central function, circulatory function, and digestive function. Therefore, a compound (agonist, angiogonist) that changes the binding property between the receptor protein and the ligand of the present invention and the ligand for the receptor protein of the present invention are dysfunctional of the receptor protein of the present invention. It can be used as a prophylactic and / or therapeutic agent for diseases related to.
  • examples of the disease associated with the dysfunction of the receptor protein of the present invention include central diseases (eg, Alzheimer's disease, dementia, eating disorders, depression, epilepsy, etc.), endocrine diseases (eg, Addison's disease, Cushing's syndrome, pheochromocytoma, primary aldosteronism, menopause, endometriosis, gonadal dysfunction, thyroid dysfunction, pituitary dysfunction, etc., metabolic diseases (eg, diabetes, dyslipidemia, diabetic complications) , Obesity, gout, cataract, hyperlipidemia, etc.), cancer (for example, non-small cell lung cancer, ovarian cancer, prostate cancer, stomach cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, etc.) , Inflammatory diseases (eg, allergy, asthma, rheumatism, arthritis, nephritis, hepatitis, retinopathy, cystitis, pneumonia, etc.), cardiovascular diseases (eg, hypertension, cardiac hypertrophy) An
  • the compound or ligand when used as a prophylactic and / or therapeutic agent for a disease associated with dysfunction of the receptor protein of the present invention, it can be formulated according to conventional means.
  • the compound or ligand may be orally administered as a sugar-coated tablet, tablet, elixir, microcapsule, or the like, if necessary, or mixed with water or another pharmaceutically acceptable liquid. It can be used parenterally in the form of injections, such as sterile solutions or suspensions.
  • the compound may be formulated in a unit dosage form required for generally accepted pharmaceutical practice with known physiologically acceptable carriers, flavoring agents, excipients, vehicles, preservatives, stabilizers, binders and the like. It can be manufactured by mixing. The amount of the active ingredient in these preparations is such that a suitable dosage in the specified range can be obtained.
  • Additives that can be incorporated into tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc. Swelling agents such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, and flavoring agents such as peppermint, cocoa oil or cherry.
  • the unit dosage form is a capsule, the above type of material can further contain a liquid carrier such as an oil or fat.
  • Sterile compositions for injection can be formulated according to standard pharmaceutical practice, such as dissolving or suspending the active substance in vehicles such as water for injection, and naturally occurring vegetable oils such as sesame oil and coconut oil. it can.
  • aqueous liquid for injection include physiological saline, isotonic solution containing glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.) and the like.
  • Agent for example, alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, polyethylene Cole) and nonionic surfactants (eg, Polysorbate 80 TM, HCO-50).
  • As the oily liquid for example, sesame oil, soybean oil and the like are used, and may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol.
  • prophylactic and / or therapeutic agent examples include a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride, etc.), a stabilizer (for example, , Human serum albumin, polyethylene glycol, etc.), preservatives (eg, benzyl alcohol, phenol, etc.), antioxidants and the like.
  • a buffer for example, a phosphate buffer, a sodium acetate buffer
  • a soothing agent for example, benzalkonidum chloride, proactive hydrochloride, etc.
  • a stabilizer for example, Human serum albumin, polyethylene glycol, etc.
  • preservatives eg, benzyl alcohol, phenol, etc.
  • antioxidants and the like examples include a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride
  • prophylactic and / or therapeutic agent can be used in combination with an appropriate drug, for example, as a DDS preparation in which an organ or tissue in which the receptor protein of the present invention is highly expressed is a specific target.
  • the preparations obtained in this way are safe and have low toxicity, so they can be used in mammals (eg, humans, rats, mice, puppies, sheep, pigs, puppies, cats, dogs, monkeys, etc.). Can be administered.
  • the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptom, administration method, and the like.
  • the single dose varies depending on the administration target, target organ, symptoms, administration method, and the like.
  • the dose can be administered in terms of 60 kg.
  • the antibody of the present invention can specifically recognize the receptor protein of the present invention and the like, the quantification of the receptor protein and the like of the present invention in a test solution, particularly sandwich It can be used for quantification by Tsuchi immunoassay. That is, the present invention provides, for example,
  • one of the antibodies is an antibody that recognizes the N-terminal of the receptor protein of the present invention or the like, and the other antibody is an antibody that reacts with the C-terminal of the receptor protein or the like of the present invention.
  • the other antibody is an antibody that reacts with the C-terminal of the receptor protein or the like of the present invention.
  • the receptor protein and the like of the present invention can be measured using a monoclonal antibody against the receptor protein and the like of the present invention (hereinafter sometimes referred to as the monoclonal antibody of the present invention), and detection by tissue staining and the like can be performed. You can also.
  • the antibody molecule itself may be used, or F (ab ') 2 , Fab', or Fab fraction of the antibody molecule may be used.
  • the measurement method using an antibody against the receptor protein of the present invention is not particularly limited, and may be an antibody, an antigen or an antibody corresponding to the amount of an antigen (for example, the amount of the receptor protein) in a test solution.
  • any method that detects the amount of one antigen complex by chemical or physical means and calculates this from a standard curve prepared using a standard solution containing a known amount of the antigen can be used. You may. For example, nephelometry, a competitive method, an immunometric method and a sandwich method are suitably used, but it is particularly preferable to use a sandwich method described later in terms of sensitivity and specificity.
  • a labeling agent used in a measuring method using a labeling substance for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance and the like are used.
  • the radioisotope for example, [ 125 I], [ 131 I], [ 3 H], [ 14 C] and the like are used.
  • the enzyme a stable enzyme having a large specific activity is preferable. For example, / 3-galactosidase, / 3-dalcosidase, alkaline phosphatase, peroxidase, malic acid Dehydrogenase and the like are used.
  • fluorescent substance for example, fluorescamine, fluorescein isothiosinate and the like are used.
  • luminescent substance for example, luminol, luminol derivative, luciferin, lucigenin and the like are used.
  • a biotin-avidin system can be used for binding the antibody or antigen to the labeling agent.
  • insolubilization of the antigen or antibody physical adsorption may be used, or a method using a chemical bond usually used for insolubilizing or immobilizing a protein or enzyme may be used.
  • the carrier for example, insoluble polysaccharides such as agarose, dextran, and cellulose, synthetic resins such as polystyrene, polyacrylamide, and silicon, and glass are used.
  • the test solution is reacted with the insolubilized monoclonal antibody of the present invention (primary reaction), and further reacted with the labeled monoclonal antibody of the present invention (secondary reaction).
  • primary reaction the insolubilized monoclonal antibody of the present invention
  • secondary reaction the labeled monoclonal antibody of the present invention
  • the primary reaction and the secondary reaction may be performed in the reverse order, may be performed simultaneously, or may be performed at staggered times.
  • the labeling agent and the method of insolubilization can be based on those described above.
  • the antibody used for the solid phase antibody or the labeling antibody is not necessarily one kind, and a mixture of two or more kinds of antibodies is used for the purpose of improving measurement sensitivity and the like. May be used.
  • the monoclonal antibody of the present invention used in the primary reaction and the secondary reaction is preferably an antibody having different binding sites such as receptor proteins. That is, when the antibody used in the primary reaction and the secondary reaction is, for example, the antibody used in the secondary reaction recognizes the C-terminal of the receptor protein, the antibody used in the primary reaction is preferably the C-terminal. For example, an antibody that recognizes other than the N-terminal part is used. ⁇
  • the monoclonal antibody of the present invention can be used in a measurement system other than the sandwich method, for example, a competition method, an immunometric method, or a nephrometry.
  • competition method the antigen in the test solution and the labeled antigen were allowed to react competitively with the antibody.
  • the unreacted labeled antigen is separated from (F) and the labeled antigen (B) bound to the antibody (BZF separation), and the amount of either B or F is measured, and the amount of antigen in the test solution is determined. Quantify.
  • a soluble antibody is used as the antibody
  • BZF separation is carried out using a polyethylene glycol
  • a liquid phase method using a second antibody against the above antibody or a solid phase antibody is used as the first antibody.
  • An immobilization method using a soluble antibody as the first antibody and using an immobilized antibody as the second antibody is used.
  • the antigen in the test solution and the immobilized antigen are subjected to a competitive reaction with a certain amount of labeled antibody, and then the solid phase and the liquid phase are separated. After reacting the antigen with an excess amount of the labeled antibody, the immobilized antigen is added to bind the unreacted labeled antibody to the solid phase, and then the solid phase and the liquid phase are separated. Next, the amount of label in either phase is measured to determine the amount of antigen in the test solution.
  • nephelometry the amount of insoluble sediment generated as a result of an antigen-antibody reaction in a gel or in a solution is measured. Even when the amount of antigen in the test solution is small and only a small amount of sediment is obtained, laser nephrometry utilizing laser scattering is preferably used.
  • the receptor protein or its salt of the present invention can be quantified with high sensitivity.
  • the antibody of the present invention can be used for specifically detecting the receptor protein of the present invention present in a subject such as a body fluid or a tissue. Further, preparation of an antibody column used for purifying the receptor protein of the present invention and the like, detection of the receptor protein of the present invention in each fraction at the time of purification, and the present invention in a test cell It can be used for analyzing the behavior of the receptor protein.
  • the antibody of the present invention can specifically recognize the receptor protein of the present invention or its partial peptide or a salt thereof, the receptor protein of the present invention or its partial peptide in the cell membrane can be recognized. Can be used for screening a compound that changes the amount of the compound.
  • a cell membrane fraction is isolated, and the receptor of the present invention contained in the cell membrane fraction is isolated.
  • the cell membrane fraction After disrupting the transformant expressing the receptor protein or its partial peptide of the present invention, the cell membrane fraction is isolated, and the receptor protein of the present invention contained in the cell membrane fraction is isolated. Alternatively, the amount of the receptor protein of the present invention or its partial peptide in the cell membrane is changed by quantifying the partial peptide thereof.
  • Compound screening method
  • the present invention provides a method for screening a compound that changes the amount of the receptor protein of the present invention or its partial peptide in a cell membrane by confirming the protein on the cell membrane by quantifying the degree of staining of the protein.
  • non-human mammals eg, mice, rats, rabbits, sheep, sheep, bush, birds, cats, dogs, monkeys, etc., more specifically, dementia rats, obese mice, arteries, etc.
  • Drugs eg, anti-dementia drugs, antihypertensive drugs, anti-cancer drugs, anti-obesity drugs, etc.
  • physical stress eg, flooding stress, electric shock, light / dark, low temperature, etc.
  • blood or a specific organ eg, brain, liver, spleen, large intestine, knee, ovary, etc.
  • a tissue or cell isolated from the organ is obtained.
  • the obtained organ, tissue or cell is suspended in, for example, an appropriate buffer (for example, Tris-HCl buffer, phosphate buffer, Hess buffer, etc.) to destroy the organ, tissue or cell
  • an appropriate buffer for example, Tris-HCl buffer, phosphate buffer, Hess buffer, etc.
  • a cell membrane fraction is obtained by using a surfactant (eg, Triton XI 00 TM, Twin 20 TM, etc.), and further using a method such as centrifugation, filtration, or column fractionation.
  • a surfactant eg, Triton XI 00 TM, Twin 20 TM, etc.
  • the cell membrane fraction refers to a cell membrane-rich fraction obtained by disrupting cells and then obtained by a known method.
  • Cell crushing methods include a method of crushing cells with a Potter-Elvehj em-type homogenizer, Warinda Blender ⁇ Polytron.
  • Fine Fractionation by centrifugal force is mainly used for fractionation of the cell membrane.
  • the cell lysate is centrifuged at a low speed (500 rpm to 300 rpm) for a short time (usually about 1 minute to 10 minutes), and the supernatant is further spun at a higher speed (150 rpm to 300 rpm).
  • the mixture is centrifuged at 0,000 rpm for 30 minutes to 2 hours, and the resulting precipitate is used as the membrane fraction.
  • the membrane fraction is rich in expressed receptor proteins and membrane components such as cell-derived phospholipids and membrane proteins.
  • the receptor protein of the present invention or its partial peptide contained in the cell membrane fraction can be quantified by, for example, a sandwich immunoassay using the antibody of the present invention, Western blot analysis, or the like.
  • Such a sandwich immunoassay can be performed in the same manner as described above, and the Western plot can be performed by known means.
  • Screening for a compound that alters the amount of the receptor protein of the present invention or its partial peptide in the cell membrane is performed by:
  • a given time before drug or physical stress is applied to a normal or disease model non-human mammal (30 minutes to 24 hours before, preferably 30 minutes to 12 hours before, Preferably 1 hour to 6 hours before) or after a certain time (30 minutes to 3 days, preferably 1 hour to 2 days, more preferably 1 hour to 24 hours), or drug or physical
  • the test compound is administered at the same time as the target stress, and after a certain period of time after administration (30 minutes to 3 days, preferably 1 hour to 2 days, more preferably 1 hour to 24 hours), the cell membrane
  • test compound When culturing the transformant according to a conventional method, the test compound is mixed in a medium, and after culturing for a certain period of time (1 day to 7 days, preferably 1 day to 3 days, more preferably 2 days to 3 days) (After day), by quantifying the amount of the receptor protein of the present invention or its partial peptide in the cell membrane.
  • the receptor protein of the present invention contained in a cell membrane fraction or a partial peptide thereof
  • the confirmation of the code is specifically performed as follows.
  • non-human mammals eg, mice, rats, rabbits, sheep, sheep, bush, birds, cats, dogs, monkeys, etc .; more specifically, dementia rats, obese mice, arteries, etc.
  • Drugs eg, anti-dementia drugs, antihypertensive drugs, anti-cancer drugs, anti-obesity drugs, etc.
  • physical stress eg, flooding stress, electric shock, light / dark, low temperature, etc.
  • blood, or specific organs eg, brain, liver, spleen, large intestine, kidney, ovary, etc.
  • tissues or cells isolated from the organs are obtained.
  • the obtained organs, tissues or cells are cut into tissue sections according to a conventional method, and immunostaining is performed using the antibody of the present invention.
  • immunostaining is performed using the antibody of the present invention.
  • the compound obtained by using the screening method of the present invention or a salt thereof is a compound having an action of changing the amount of the receptor protein of the present invention or a partial peptide thereof in a cell membrane.
  • the cell stimulating activity via G protein-coupled receptor eg, arachidonic acid release, acetylcholine release, intracellular C a2 + release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuations, intracellular protein phosphorylation, activation of c-fos, decrease in pH, etc.
  • G protein-coupled receptor eg, arachidonic acid release, acetylcholine release, intracellular C a2 + release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuations, intracellular protein phosphorylation, activation of c-fos, decrease in pH, etc.
  • G protein-coupled receptor eg, arachid
  • the compound examples include a peptide, a protein, a non-peptidic compound, a synthetic compound, and a fermentation product. These compounds may be a novel compound or a known compound.
  • the compound that enhances the cell stimulating activity is useful as a safe and low toxic drug for enhancing the physiological activity of the receptor protein of the present invention or the like.
  • the compound that reduces the cell stimulating activity is useful as a safe and low-toxic drug for reducing the physiological activity of the receptor protein of the present invention or the like.
  • a compound or a salt thereof obtained by using the screening method of the present invention is used as a pharmaceutical composition, it can be carried out according to a conventional method.
  • tablets, capsules, elixirs, microcapsules, sterile solutions, suspensions, and the like can be prepared in the same manner as the above-mentioned drug containing the receptor protein of the present invention.
  • the preparations obtained in this way are safe and have low toxicity, they can be used, for example, in mammals (eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.). Can be administered.
  • mammals eg, humans, rats, mice, egrets, sheep, bush, foxes, cats, dogs, monkeys, etc.
  • the dose of the compound or a salt thereof varies depending on the administration subject, target organ, condition, administration method, and the like. However, in the case of oral administration, for example, in a cancer patient (assuming 60 kg), one dose is required. About 0.1 to per day: L0 O mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg. In the case of parenteral administration, the single dose varies depending on the administration target, target organ, symptoms, administration method, etc. For example, in the case of injection, it is usually, for example, a cancer patient (as 6 O kg) About 0.01 to 3 O mg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 1 O mg per day. It is. In the case of other animals, the amount converted per 60 kg can be administered.
  • a preventive and / or therapeutic agent for various diseases containing a compound that alters the amount of the receptor protein of the present invention or its partial peptide in the cell membrane containing a compound that alters the amount of the receptor protein of the present invention or its partial peptide in the cell membrane.
  • the receptor protein of the present invention is, for example, as described above. It is thought to play some important role in vivo, such as central functions. Therefore, a compound that alters the amount of the receptor protein of the present invention or its partial peptide in the cell membrane can be used as an agent for preventing and / or treating a disease associated with dysfunction of the receptor protein of the present invention. .
  • diseases associated with dysfunction of the receptor protein of the present invention include: For example, central illness (eg, Alzheimer's disease, dementia, eating disorder, depression, epilepsy, etc.), endocrine disease (eg, Addison's disease, Cushing's syndrome, brown cell type, primary aldosteronism, menopause, endometriosis , Dysgonadism, thyroid dysfunction, pituitary dysfunction, etc.), metabolic diseases (eg, diabetes, lipid metabolism, diabetic complications, obesity, gout, cataract, hyperlipidemia, etc.), cancer (eg, non-small) Cell lung cancer, ovarian cancer, prostate cancer, stomach cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, etc.), inflammatory diseases (eg, allergy, asthma, rheumatism, arthritis, nephritis, hepatitis, hepatitis, Retinopathy, cystitis, pneumonia, etc.), cardiovascular diseases (eg, hypertension, cardiac hypertrophy, angina, ar
  • the compound when used as a prophylactic and / or therapeutic agent for a disease associated with dysfunction of the receptor protein of the present invention, it can be formulated according to conventional means.
  • the compound can be used as a sugar-coated tablet, capsule, elixir, microcapsule or the like as needed, orally, or aseptic solution with water or another pharmaceutically acceptable liquid. It can be used parenterally or in the form of injections such as suspensions.
  • the compound is mixed with known physiologically acceptable carriers, flavoring agents, excipients, vehicles, preservatives, stabilizers, binders, and the like in a unit dosage form generally required for the practice of pharmaceutical preparations. It can be manufactured by the following. The amount of the active ingredient in these preparations is such that a suitable dosage in the specified range can be obtained.
  • additives that can be mixed with tablets, capsules, etc.
  • binders such as gelatin, corn starch, tragacanth, gum arabic, and crystalline cells.
  • Excipients such as loin, leavening agents such as corn starch, gelatin, alginic acid, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose or saccharine, peppermint, coconut oil or cherry.
  • sweeteners such as sucrose, lactose or saccharine, peppermint, coconut oil or cherry.
  • sweeteners such as sucrose, lactose or saccharine, peppermint, coconut oil or cherry.
  • the unit dosage form is a capsule, the above type of material can further contain a liquid carrier such as an oil or fat.
  • Sterile compositions for injection can be formulated according to standard pharmaceutical practice, such as dissolving or suspending the active substance in vehicles such as water for injection, and naturally occurring vegetable oils such as sesame oil and coconut oil. it can.
  • aqueous solution for injection for example, physiological saline, isotonic solution containing glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.) and the like are used.
  • Agents such as alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, polyethylene daricol), nonionic surfactants (eg, polysorbate 80 TM, HCO-50) .
  • oily liquid for example, sesame oil, soybean oil and the like are used, and may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol.
  • prophylactic and / or therapeutic agent examples include a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride, etc.), a stabilizer (for example, , Human serum albumin, polyethylene glycol, etc.), preservatives (eg, benzyl alcohol, phenol, etc.), antioxidants and the like.
  • a buffer for example, a phosphate buffer, a sodium acetate buffer
  • a soothing agent for example, benzalkonidum chloride, proactive hydrochloride, etc.
  • a stabilizer for example, Human serum albumin, polyethylene glycol, etc.
  • preservatives eg, benzyl alcohol, phenol, etc.
  • antioxidants and the like examples include a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonidum chloride, proactive hydrochloride
  • preparations obtained in this way are safe and low toxic, they can be used, for example, in mammals (eg, humans, rats, mice, puppies, higgs, bush, puppies, cats, dogs, monkeys, etc.). Can be administered.
  • mammals eg, humans, rats, mice, puppies, higgs, bush, puppies, cats, dogs, monkeys, etc.
  • the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptoms, administration method, and the like.
  • oral administration for example, in a patient with cancer (6 O kg), the About 0.1 to per day: L 0 O mg, preferably about 1.0 to 5 O mg, more preferably about 1.0 to 20 mg.
  • parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, etc.
  • an injection for example, in a cancer patient (as 60 kg), about 0.01 to 3 Omg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 1 Omg per day It is convenient to administer the degree by intravenous injection. In the case of other animals, the dose can be administered in terms of 60 kg.
  • the neutralizing activity of an antibody against the receptor protein of the present invention or its partial peptide or a salt thereof against the receptor protein or the like means that it inactivates a signal transduction function involving the receptor protein.
  • cell stimulating activity via the receptor protein for example, arachidonic acid release, acetylcholine release, intracellular Ca 2 + Activation or suppression that promotes release
  • transgenic animals expressing the receptor protein of the present invention and the like can be produced.
  • animals include mammals (for example, rats, mice, egrets, sheep, bushfishes, sea lions, cats, cats, dogs, monkeys, etc.) (hereinafter sometimes abbreviated as animals). , Mice, and egrets are preferred.
  • the DNA of the present invention In transferring the DNA of the present invention to a target animal, it is generally advantageous to use the DNA as a gene construct linked downstream of a promoter capable of being expressed in animal cells.
  • a DNA construct of the present invention which is highly homologous to the DNA and is linked to the downstream of various promoters capable of expressing the DNA of the present invention in animal cells, may be used, for example.
  • To heron fertilized egg By microinjection, a DNA-transferred animal that highly produces the receptor protein of the present invention can be produced.
  • a promoter derived from a virus or a ubiquitous expression promoter such as meta-mouth thionein can be used, but an NGF gene promoter specifically expressed in the brain and a phenolase gene promoter are preferably used.
  • the presence of the receptor protein or the like of the present invention in the germinal cells of the produced animal after DNA transfer means that all the offspring of the produced animal have the receptor protein of the present invention in all of its germ cells and somatic cells Means The progeny of this type of animal that has inherited the gene has the receptor protein of the present invention in all of its germ cells and somatic cells.
  • the DNA-transferred animal of the present invention After confirming that the DNA-transferred animal of the present invention stably retains the gene by breeding, it can be reared in a normal breeding environment as the DNA-bearing animal. Furthermore, by crossing male and female animals having the target DNA, homozygous animals having the transgene on both homologous chromosomes are obtained, and by crossing the male and female animals, all the offspring will have the DNA Breeding to have Since the animal into which the DNA of the present invention has been transferred has a high level of expression of the receptor protein of the present invention, etc., it is used for screening of an agonist or an angiosperm against the receptor protein of the present invention. Useful as animals.
  • the DNA-transferred animal of the present invention can also be used as a cell source for tissue culture.
  • the present invention can be used. It can analyze the quality of protein at the reception and evening.
  • Cells of a tissue having the receptor protein of the present invention and the like are cultured by standard tissue culture techniques, and the functions of cells from tissues that are generally difficult to culture such as those derived from the brain and peripheral tissues are used by these. Can study.
  • a drug that enhances the function of various tissues can be selected.
  • Trt Trityl
  • DCC N, N'-dicyclohexylcarbodiimide
  • sequence numbers in the sequence listing in this specification indicate the following sequences.
  • FIG. 1 shows the amino acid sequence of the novel human-derived G protein-coupled receptor protein TGR 20-1 of the present invention.
  • FIG. 1 shows the nucleotide sequence of cDNA encoding the novel human G protein-coupled receptor protein TGR20-11 of the present invention.
  • SEQ ID NO: 5 shows the nucleotide sequence of primer 2 used in the PCR reaction in Example 1 below.
  • FIG. 1 shows the amino acid sequence of a novel human-derived G protein-coupled receptor protein TGR20-2 of the present invention.
  • FIG. 1 shows the nucleotide sequence of cDNA encoding the novel human-derived G protein-coupled receptor protein TGR 20-2 of the present invention.
  • SEQ ID NO: 7 The base sequence of the primer 13 used in the PCR reaction in Examples 2 and 3 below is shown.
  • FIG. 3 shows the nucleotide sequence of a positive primer TGR20TQF used in Example 3 below.
  • Example 7 shows the nucleotide sequence of probe TGR20TQP used in Example 3 below.
  • T0P10 / pCR2.1-TGR20-1 is an independent administrative corporation of Chuo No. 6 (Zip code 305-8566), 1-chome, Tsukuba-Higashi, Ibaraki, Japan since April 19, 2001 At the National Institute of Advanced Industrial Science and Technology, Patent Depositary Depositary No. FE RM BP-7552, 2-17-85, Jusanhoncho, Yodogawa-ku, Osaka, Osaka from April 11, 2001 (postal code 532) -8686) has been deposited with the Fermentation Research Institute (IFO) under the deposit number IF ⁇ 16612.
  • IFO Fermentation Research Institute
  • TOP10 / pCR2.TGR20-2 is an independent administrative corporation of Tsukuba-Higashi 1-chome 1 Chuo No. 6 (Zip code 305-8566) from April 19, 2001 (Heisei 13) Deposited at the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary under the deposit number FERM BP-7553, from April 11, 2001, 2-17-85, Jusanhoncho, Yodogawa-ku, Osaka-shi, Osaka (Postal code 532-8686) ) And deposited with the Fermentation Research Institute (IFO) under the deposit number IF ⁇ 16613.
  • IFO Fermentation Research Institute
  • PCR reaction was performed using two primers, primer 1 (SEQ ID NO: 3) and primer 2 (SEQ ID NO: 4).
  • the composition of the reaction solution for this reaction was as follows, using the above cDNA as type 3 / ⁇ , 11 volumes of Advantage-GC2 Polymerase Mix (CL0NTECH), primer 1 (SEQ ID NO: 3) and primer 1 (SEQ ID NO: 2). : 4) was added to each of 0.5 zM, dNTPs to 200 zM, buffer attached to the enzyme to 101, and GCMdt to 51 to make a liquid volume of 50 l.
  • the PCR reaction product was subcloned into a plasmid vector pCR2.1 (Invitrogen) according to the prescription of a T0P0-TA cloning kit (Invitrogen). This was introduced into E. coli TOP10, and clones having cDNA were selected on LB agar medium containing ampicillin.
  • a cDNA sequence (SEQ ID NO: 2) encoding a novel G protein-coupled receptor Yuichi protein was obtained.
  • a novel G protein-coupled receptor protein containing these amino acid sequences was named TGR20-1.
  • the transformant was named Escherichia coli T0P10 / pCR2.1-TGR20-1.
  • TGR 20-1 The hydrophobicity plot of TGR 20-1 is shown in FIG. Example 2 Cloning of cDNA encoding human testis-derived G protein-coupled receptor Yuichi protein and determination of nucleotide sequence
  • a PCR reaction was performed using two primers, primer 1 (SEQ ID NO: 3) and primer 3 (SEQ ID NO: 7).
  • the composition of the reaction solution used in the reaction was as follows, using the above cDNA as a 3 l ⁇ form, the amount of Advantage-GC2 Polymerase Mix (CL0NTECH), primer 1 (SEQ ID NO: 3) and primer 1 (SEQ ID NO: 7).
  • dNTPs 200 ⁇ l, buffer attached to the enzyme 101 and GCMelt 51 were added to make a volume of 501.
  • the PCR reaction product was subcloned into a plasmid vector pCR2.1 (Invitrogen) according to the prescription of a T0P0-TA cloning kit (Invitrogen). This was introduced into E. coli T0P10, and clones having cDNA were selected on LB agar medium containing ampicillin.
  • a cDNA sequence (SEQ ID NO: 6) encoding a novel G protein-coupled receptor Yuichi protein was obtained.
  • the novel G protein-coupled receptor protein containing these amino acid sequences was named TGR20-2.
  • the transformant was named Escherichia coli (fod? 7'd? / 'A coli) T0P10 / pCR2. TGR20-2.
  • TGR20 TGR20-1 and TGR20-2 (hereinafter, these may be simply abbreviated as TGR20) using TaqManPCR
  • primers and probes were designed using Primer Express ver.1.0 (PE Biosystems Japan), forward primer TGR20TQF (5'-AAGTC AGAGG AGAGG AGGAC ACA-3 '(SEQ ID NO: 8)), reverse primer TGR20TQR (5'-TGAAT CATTT TGCAG GCCTG-3 '(SEQ ID NO: 9)) and probe TGR20TQP (5, -TGTGT TGGCT GGCAC TCTGT GGAGA A-3' (SEQ ID NO: 10)) were prepared.
  • the reporter dye of the probe added FAM (6-carboxyfluorescein).
  • a PCR fragment obtained by amplifying pCR2. was purified by], it was used to prepare the 10 fl one 106 copies I 5 ⁇ 1.
  • cDNA libraries prepared using the SMART RACE Library System of CL0NTECH were used as the cDNA source for each tissue.
  • the TGR20 tissue distribution was compared by measuring the / 3-actin expression level using TaaMan / 3-actin control reagents Mix (PE Biosystems Japan) and normalizing it.
  • TadMan PCR uses TatiMan Universal PCR Master Mix (PE Biosystems Japan). The reaction was performed using ABI PRISM 7700 Sequence Detection System (PE Biosystems Japan) according to the attached instructions.
  • the G protein-coupled receptor protein of the present invention or its partial peptide or a salt thereof, and the polynucleotide encoding the receptor protein or its partial peptide are: (2) Acquisition of antibodies and antisera, (3) Construction of a recombinant receptor protein overnight expression system, (4) Development of a receptor-integrated atsushi system using the same expression system ⁇ Screening of drug candidate compounds, 5 Performing drug design based on comparison with structurally similar ligands ⁇ Receptors 6 Probes in gene diagnosis ⁇ Reagents for creating PCR primers 7 Transgeneic It can be used for animal production or as a drug such as a gene therapy agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une protéine de récepteur couplé par protéine g ou certains de ses fragments peptides ou sels et des polynucléotides, par exemple l'ADN, l'ARN, codant cette protéine de récepteur ou certains de ses fragments peptides ou de ses dérivés. On peut les utiliser (1) pour déterminer un ligand ou un agoniste, (2) pour acquérir un anticorps ou un antisérum, (3) pour construire un système d'expression de protéine d'un récepteur recombinant, (4) pour mettre au point un système d'essai lié au récepteur et de recherche systématique d'un candidat composé pour un médicament avec utilisation du système d'expression, (5) pour réaliser la conception d'un médicament sur la base d'une comparaison avec un ligand ou un récepteur de structure similaire, (6) comme réactif pour construire une sonde en diagnostic génique ou une amorce de réaction en chaîne de polymérase, (7) pour construire un animal transgénique, ou (8) comme médicament tel qu'un médicament génétique.
PCT/JP2002/004200 2001-04-27 2002-04-26 Proteine de recepteur couple par proteine g et adn comportant cette proteine WO2002088356A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001133244 2001-04-27
JP2001-133244 2001-04-27

Publications (1)

Publication Number Publication Date
WO2002088356A1 true WO2002088356A1 (fr) 2002-11-07

Family

ID=18981133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/004200 WO2002088356A1 (fr) 2001-04-27 2002-04-26 Proteine de recepteur couple par proteine g et adn comportant cette proteine

Country Status (1)

Country Link
WO (1) WO2002088356A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024891A1 (fr) * 1998-10-28 2000-05-04 Takeda Chemical Industries, Ltd. Nouvelles proteines receptrices couplees aux proteines g et adn de celles-ci
WO2001036473A2 (fr) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Recepteurs couples a une proteine g

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024891A1 (fr) * 1998-10-28 2000-05-04 Takeda Chemical Industries, Ltd. Nouvelles proteines receptrices couplees aux proteines g et adn de celles-ci
WO2001036473A2 (fr) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Recepteurs couples a une proteine g

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIBERT F. ET AL.: "Selective amplification and cloning of four new members of the G protein-coupled receptor family", SCIENCE, vol. 244, no. 4904, 1989, pages 569 - 572, XP002952936 *
SCHOENEBERG T. ET AL.: "A novel subgroup of class I G-protein-coupled receptors", BIOCHIM. BIOPHYS. ACTA, vol. 1446, no. 1-2, 1999, pages 57 - 70, XP002952935 *

Similar Documents

Publication Publication Date Title
WO2000049046A1 (fr) Nouvelle proteine de recepteur couplee a la proteine g et adn
WO2001094582A1 (fr) Nouvelle proteine de recepteur couple a la proteine g et adn pour cette proteine de recepteur
WO2001083748A1 (fr) Proteine de recepteur couple a la proteine g et adn correspondant
WO2002004640A1 (fr) Nouvelle proteine du type recepteur couple aux proteines g et adn correspondant
WO2002022665A1 (fr) Proteines de recepteur couple a la proteine g et adn correspondants
WO2002006466A1 (fr) Nouvelle proteine gr et son adn
WO2001096567A1 (fr) Nouvelle proteine receptrice couplee a la proteine g et adn de ce recepteur
WO2000035953A1 (fr) Nouvelle proteine recepteur couplee a une proteine g et son adn
WO2002088356A1 (fr) Proteine de recepteur couple par proteine g et adn comportant cette proteine
WO2002053593A1 (fr) Nouvelle proteine de recepteur couple a la proteine g et adn de celle-ci
WO2001073021A1 (fr) Nouvelle proteine receptrice couplee a une proteine g et adn associe
WO2002002767A1 (fr) Proteine de recepteur couple a la proteine g et adn correspondant
WO2001077326A1 (fr) Proteine receptrice couplee a la proteine g et son adn
WO2002002770A1 (fr) Nouvelle proteine receptrice couplee a une proteine g et adn associe
WO2002088182A1 (fr) Nouvelle proteine des recepteurs couples aux proteines-g et adn associe
JP2002355052A (ja) 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ
WO2002004624A1 (fr) Nouvelle proteine receptrice couplee a la proteine g et adn destine a celle-ci
WO2002057309A1 (fr) Nouvelle proteine receptrice couplee a la proteine g et adn de cette proteine
JP2002355050A (ja) 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ
JP2002355053A (ja) 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ
JP2003024088A (ja) 新規ｇタンパク質共役型レセプタータンパク質およびそのｄｎａ
US20040048263A1 (en) Novel g protein-coupled receptor protein and dna thereof
WO2002004641A1 (fr) Nouvelle proteine receptrice couplee a la proteine g et son adn
US20040101875A1 (en) Novel g protein-coupled receptor protein and dna thereof
WO2002046394A1 (fr) Nouvelle proteine des recepteurs lies aux proteines g et adn associe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP